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DIETARY SUPPLEMENTS: A REVIEW OF
UNITED STATES REGULATION WITH EMPHASIS
ON THE DIETARY SUPPLEMENT HEALTH AND





This paper is submitted in satisfaction of both the course requirement and the third year written work
requirement
ABSTRACT
This paper undertakes a review of notable dietary supplement regulation in the United States.
First, this paper discusses dietary supplements generally and their uses and economic characteris-
tics. Second, this paper discusses a brief general history of dietary supplement regulation in the
United States including the Dietary Supplement Health and Education Act of 1994 (“DSHEA”).
Emphasis is placed on the DSHEA and notable post-DSHEA governance in the form of Food and
Drug Administration regulations, congressional activity, and other administrative and industry ac-
tion. Finally, this paper proposes how the United States, both through government regulation and
industry self-regulation, should proceed to handle dietary supplements in 2004 and beyond.
1I. INTRODUCTION
Food and drugs – at ﬁrst glance they seem worlds apart but upon closer inspection their boundaries start
to merge. For decades, Congress and the Food and Drug Administration (“FDA”) struggled to deﬁne such
boundaries until they ﬁnally created an intermediate product group called dietary supplements. The Dietary
Supplement Health and Education Act of 1994 (“DSHEA”) established the statutory category of dietary
supplements and subjected them to various food standards as well as a host of new standards.1 The DSHEA
attempted to strike a balance between foods that are functional in that they have some health beneﬁts and
drugs that have clearly deﬁned and approved health beneﬁts. Since passage of the DSHEA, Congress, the
FDA, and the dietary supplement industry have strove, with varying degrees of success, to implement the
DSHEA and give deﬁnition to the ever expanding and extremely popular dietary supplement market.
II. GENERAL BACKGROUND REGARDING DIETARY SUPPLEMENTS
A. Types of Dietary Supplements
Dietary supplements are deﬁned in the DSHEA (now codiﬁed in scattered sections of Title 21 of the United
States Code) as a product other than tobacco which includes one or more of the following dietary ingredients:
a vitamin, a mineral, an herb or other botanical, an amino acid, any other substance used to supplement the
diet by increasing total dietary intake, or a concentrate, metabolite, constituent, extract, or combination of
any of the above.2 Whatever the form, dietary supplements are considered a special category of food and
1Pub. L. No. 103-417, 108 Stat. 4325 (1994) (codiﬁed as amended in scattered sections of 21 U. S. C.).
2Pub. L. No. 103-417, § 3 (codiﬁed at 21 U. S. C. § 321(ﬀ)(1)(A-F)). A dietary supplement also must be intended for
ingestion in tablet, capsule, powder, soft gel, or liquid form. Id. (codiﬁed at 21 U. S. C. §§ 321(ﬀ)(2)(A)(i), 350(c)(1)(B)(i)).
Further, if the dietary supplement is not intended for ingestion in such form, it must not be represented as conventional food
and not represented as meal replacement. Id. (codiﬁed at 21 U. S. C. §§321(ﬀ)(2)(A)(ii), 350(c)(1)(B)(ii)). Further, the dietary
supplement, no matter the form, must not be represented for use as conventional food or meal replacement. Id. (codiﬁed at 21
U. S. C. § 321(ﬀ)(2)(B). Further, the dietary supplement must be labeled as a dietary supplement. Id. (codiﬁed at 21 U. S. C.
2are not considered drugs.3
The main categories of dietary supplements in the United States are as follows: vitamins,4 minerals,5 herbals
and botanicals (including extracts),6 animal extracts,7 amino acids,8 proteins,9 concentrates, metabolites,
and constituents,10 teas,11 and miscellaneous products.12 Currently in the United States, dietary supple-
ments play a key role alongside nutraceuticals13 and functional foods14 in the ever expanding consumer
§ 321(ﬀ)(2)(C). Finally, the dietary supplement deﬁnition includes and excludes certain drugs. Id. (codiﬁed at 21 U. S. C. §
321(ﬀ)(3).
3Id. (codiﬁed at 21 U. S. C. § 321(ﬀ)); but see 21 U. S. C. § 321(ﬀ)(3) (in certain limited cases a dietary supplement can be
a drug). I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative History
and Analysis 1 (1996);
4Vitamins are deﬁned as “[p]roducts that are organic (carbon-containing) nutrients that are essential in small quantities for
normal metabolism, growth, and well-being. They must be obtained through the diet because they either are not synthesized in
the body or are not synthesized in adequate amounts.” Center for Economics Research, Research Triangle Institute,
Economic Characterization of the Dietary Supplement Industry 1-1 (Final Report 1999) [Hereinafter Economic Char-
acterization]. There are thirteen vitamins necessary for human consumption: A, D, E, K (all fat-soluble) and B1, B2, B3 ,
B6, B12, C, biotin, folic acid, and pantothenic acid (all water-soluble). Id. at 2-1.
5Minerals are deﬁned as “[p]roducts that are chemical elements in their inorganic form. ‘Minerals’ are those that are required
in amounts greater than 100mg/day, and ‘trace minerals’ are those required in lesser amounts.” Id. at 1-1. There are seventeen
minerals commonly used in dietary supplements. Id. at 2-4. See id. at 2-5 for a table of these seventeen commonly used
minerals, their occurrence in foods, and the forms they take in supplements.
6Herbal refers to leaves and stems of a plant while botanical refers to roots, seeds, fruits, and any other part of a plant in
addition to leaves and stems of a plant. Id. at 1-1, 4-14. Herbal or botanical extracts are made from any part of a plant. Id.
7Animal extracts are “[p]roducts that are extracts of made from animal parts.” Id. at 1-1. These extracts are from particular
animal tissues or glands. Id. at 4-23.
8Amino acids are “[p]roducts that contain an amino group and an acidic function.” Id. at 1-1. They are the main constituent
of proteins and are classiﬁed as either essential (not synthesized in the human body) or non-essential (synthesized in the human
body). Id. at 4-14.
9Proteins are “[p]roducts with the complete set of amino acids to make up proteins.” Id. at 1-1. They are “antibodies as
part of the immune system” and are key in regulating many body functions. Id. at 4-14.
10Concentrates, metabolites, and constituents refer to any products falling within the other deﬁnitions of dietary supplement
and broken into individual parts or components. See id. at 1-1.
11Teas refer to “[p]roducts infused in water that contain herbals, botanicals, or other... [dietary supplement] products. Basic
tea products have a standard of identity as a food product; however, many
products are a combination of tea and dietary supplements.” Id. at 1-1.
12Miscellaneous products refers to “[a]ll other products meeting the criteria of dietary supplements that cannot be classiﬁed
into the categories above. They include, for example, bee pollen,
propolis, and royal jelly; coenzyme Q; spirulina and other algaes; and nucleic acids.” Id. at 1-1.
13One deﬁnition of nutraceutical “is a product isolated or puriﬁed from foods that is generally sold in medicinal form not
usually associated with food. A nutraceutical is demonstrated to have physiological beneﬁt or provide protection against
chronic disease.” Steven Dentali, Regulation of Functional Foods and Dietary Supplements, Food Technology, June 2002, at
90. Another deﬁnition for nutraceutical is “a food, dietary supplement, or medical food that has a medical or health beneﬁt,
including the prevention and treatment of disease.” Functional Foods Market Growing, Food Technology, Dec. 2003, at 90.
14One deﬁnition of functional food is a product “similar in appearance to, or may be, a conventional food, [which] is consumed
as part of a usual diet and is demonstrated to have physiological beneﬁts and/or reduce the risk of chronic disease beyond basic
nutritional functions.” Dentali, supra note 13, at 90. Neither this deﬁnition nor the deﬁnition of nutraceutical has any current
3health market.
Dietary supplements commonly take several distinct forms. The DSHEA delineates what forms a dietary
supplement may take and thus plays a role in funneling dietary supplements into these certain forms.15
The predominate forms of dietary supplements for purchase by consumers are capsules (both hard-shell
and soft-gel), tablets, liquids (including solutions, elixirs, and syrups), powders and granules, and lozenges
(substances produced to dissolve over time in the mouth).16 Additionally, “dietary supplements are allowed
to be sold in conventional food form so long as the product ‘is not represented as conventional food and is
not represented for use as a sole item of a meal or of the diet.”’17
An illustrative part of the vast dietary supplement market is the sports supplement market.18 Currently,
sports supplements enjoy enormous popularity within the broader sports nutrition market. The sports
nutrition market includes products that “focus on boosting energy [and recovery], increasing muscle mass,
or improving muscle restoration.”19 Both dietary supplements and functional foods compose the sports
nutrition market and are mostly sold in the forms of “[n]utrition bars, energy drinks, sports beverages, and
protein mixes.”20 Current examples of nutrition bars are PowerBar and Clif Bar and current examples
of energy drinks are Invigor8, E20, and SoBe No Fear.21 B vitamins often appear in energy drinks and
legal status in the United States. Dentali, supra note 13, at 90. Often the term nutraceutical and the term functional food are
used interchangeably. Functional Foods Market Growing, supra note 13.
15See supra note 2.
16See Economic Characterization, supra note 4, at 2-14 to 2-17. Liquids should be intended for consumption in small
amounts. Dentali, supra note 13, at 90.
17Dentali, supra note 13, at 90 (quoting 21 U. S. C. § 350(c)(1)(B)(ii)).
18Sports supplements are also referred to as performance-enhancing products or ergogenic aids. Linda Milo Ohr, More for
the Sport, Food Technology, Feb. 2003, at 63.
19Id.
20Id.
21Linda Milo Ohr, In Search of More Energy, Food Technology, March 2004, at 55, 56 [hereinafter Energy]. While these
products are marketed as conventional food and not dietary supplements, they contain ingredients such as taurine, ginseng, or
guarana, which otherwise lie within the deﬁnition of dietary supplement. Were such beverages marketed as dietary supplements
they would fall within the DSHEA deﬁnition. For the interaction between conventional foods (particularly functional foods and
nutraceuticals) and dietary supplements see Dentali, supra note 13, at 89-94.
4sports beverages because of their role in energy production and tissue repair and maintenance.22 Taurine,
an amino acid, is a popular sports supplement for its fat absorbing antioxidant and membrane-stabilizing
properties.23 Vitamin E, also a popular sports supplement, is used for its role in reducing damaging free
radical activity in the body after exercise.24 Protein is used as a sports supplement to maintain muscle tissue
and is found in both soy varieties (in nutrition bars) and whey varieties.25 Other sports supplements include
creatine, which is thought to increase muscle mass and augment intense exercise capability,26 and carnitine,
a metabolite amino acid derivative used to beneﬁt sport performance and recovery.27 Some ﬁnal examples of
sports supplements used for their energy boosting properties include: guarna (botanical), ginseng (an herb),
and D-ribose (an amino acid).28
B. The Dietary Supplement Industry: Economics and Sales
There are ﬁve main dietary supplement industry groups in the United States: the Council for Responsible
Nutrition, the American Herbal Productions Association, the Nonprescription Drug Manufacturers Associa-
tion (focusing on vitamin and mineral supplements), the Utah Natural Products Alliance, and the National
Nutritional Foods Association (the largest such industry group).29
In general, the dietary supplement industry is characterized by high material costs (source costs) with much
22Ohr, supra note 18, at 63, 65.
23See Energy, supra note 21, at 56, 66.
24Ohr, supra note 18, at 65.
25Id.
26Id. at 66.
27See id. at 68.
28Energy, supra note 21, at 56, 66.
29Economic Characterization, supra note 4, at 3-1.
5lower labor costs.30 Thus the raw materials that compose dietary supplements are the most important
part of the dietary supplement industry. To handle these important raw materials, there are estimated
to be over 1,100 dietary supplement raw materials and manufacturing ﬁrms.31 The vast majority (over
78%) of these ﬁrms either solely manufactures dietary supplements or manufactures dietary supplements in
combination with other functions such as importing or exporting.32 Over 54% of dietary supplement ﬁrms
produce or handle vitamins and minerals.33 Herbals and botanicals are produced or handled in 43% of
dietary supplement ﬁrms.34
The dietary supplement market is composed of many heterogeneous products. A brief look at the def-
inition of dietary supplement under the DSHEA conﬁrms this.35 This causes the cross-price elasticity of
demand for dietary supplement to be small which in turn means there is little economic substitution eﬀect
among dietary supplements.36 The substation eﬀects between dietary supplements and non-dietary supple-
ment products are also limited.37
Dietary supplement sales have been growing rapidly. In 2002 (the most recent year for which ﬁgures are
available), retail sales of dietary supplements were $18 billion, up 4% from 200138 and up 310% from a 1997
30See id. at 2-18 to 2-19.
31Id. at 3-1. Another study in 2000 estimated there to be 1,973 such establishments. Center for Economics Research,
Research Triangle Institute, Survey of Manufacturing Practices in the Dietary Supplement Industry 2-1 (Final
Report 2000).
32See Economic Characterization, supra note 4, at 3-1. Aside from manufacturing or importing and exporting, dietary
supplement ﬁrms may also perform input supply, repacking, relabeling, encapsulating, and distribution. Id.
33Id. at 3-2.
34Id. Herbal and botanical extracts followed at 14%, teas at 10%, amino acids at 4%, and animal extracts at 2% (percentages
add to more than 100 due to overlap in production or handling by ﬁrms). Id.
35See supra notes 4-12.
36Economic Characterization, supra note 4, at 4-29.
37See id. at 4-30 to 4-31. Dietary supplements are imperfect substitutes for conventional or fortiﬁed foods because consumers
cannot receive all daily needed nutrients solely from dietary supplements. Id. at 4-30. Further, dietary supplements are
imperfect substitutes for conventional medical care because only a tiny percentage of consumers rely completely on dietary
supplements for medical care. Id. at 4-31.
38National Nutritional Foods Association, Industry Facts (2002) (citing Nutritional Business Journal), available at
http://www.nnfa.org/news/industry/index.htm.
6estimate of $5.8 billion.39 This comprised 32% of the nutrition industry.40 When dietary supplements are
combined with functional foods, the total sales for 2002 were $29.8 billon comprising 67% of the nutrition
industry.41 Among dietary supplements, vitamins led the way in 2002 with $6.2 billion in sales42, an increase
of 3% over 2001.43 According to a 1999 study, the average product price for a dietary supplement in the
United States was $17.15.44
The dietary supplement industry has a market structure that encourages rapid growth. This is because the
dietary supplement market, at least in terms of manufacturing, is not highly concentrated.45 However, some
submarkets, such as the vitamin market, are more concentrated.46 There are few dominant brands in the
dietary supplement industry and barriers to entry are not high.47 This structure is changing though as the
dietary supplement market consolidates and as new federal and industry regulations are issued.48 This may
lead to the rise of more identiﬁable dietary supplement brand names.49
Along with rapid growth in dietary supplement sales, the distribution channels for dietary supplements have
been changing. A 1999 report found that the market share of natural and health food stores was growing at
a rate of 55% while the market share of multilevel marketing ﬁrms was falling.50 Other distribution channels
for dietary supplements include drugstores, mass merchandise outlets, mail order, the Internet, healthcare
39See Economic Characterization, supra note 4, at 5-1.
40See National Nutritional Foods Association, supra note 38. The nutrition industry is comprised of functional foods,
supplements, natural and organic foods, and natural personal care products. Id.
41Id.
42Id. Herbals were second with $4.3 billion; sports nutrition took in $1.8 billion and minerals took in $1.5 billion. Id.
43Id.
44Center for Economics Research, Research Triangle Institute, Dietary Supplement Sales Information 5-11
(Final Report 1999) [Hereinafter Dietary Supplement Sales Information].
45Economic Characterization, supra note 4, at 5-14.
46See id. at 5-15.
47Id. at 5-16.
48Id.
49See id. at 6-17.
50Id. at 5-11. Multilevel marketing ﬁrms consist of “direct selling, party plans, relationship selling, person-to-person selling,
and network marketing.” Id.
7practioners, and specialty shops.51
C. Dietary Supplement Use in the United States
The uses for dietary supplements are just as varied as the types of dietary supplements available. Some rep-
resentative uses given by consumers are “to improve nutrition, to make up for uses missing in the food supply,
to decrease susceptibility to or severity of disease, or to increase energy or improve performance.”52 Some
supplements, frequently herbals and botanicals, are also taken as an alternative to conventional medicine.53
The sports nutrition industry is an illustrative example of consumer dietary supplement use. In 2001,
the sports supplement market accounted for $1.74 billion in sales.54 More broadly, the sports nutritional
functional foods market (including nutrition bars and sports and energy drinks like Gatorade) accounted for
$4.3 billion in sales in 2001.55 And in particular, the energy drink market (including both conventional foods
and dietary supplements in liquid forms) increased 465% from 1998 to 2003, and it is predicted to grow by
210% from 2003 to 2008.56
As to the prevalence of use of dietary supplements, according to a 1999 report, “two out of every ﬁve
51Id. at 5-9 to 5-13.
52U.S. Department of Health and Human Services, Use of Dietary Supplements in the United States, 1988-94 1
(1999) [Hereinafter DHHS Dietary Supplement Use].
53Id.
54Ohr, supra note 18, at 63 (citing Nutritional Business Journal). The sports supplement market includes hardcore sports
beverages, sports powders, and sports pills. Id. at 63.
55Id. at 63.
56Energy, supra note 21, at 56 (citing Mintel International Group, Ltd.). Energy drinks can contain a wide array of dietary
supplements or ingredients that would otherwise be considered dietary supplements if the product was marketed as a dietary
supplement. Examples include taruine, ginseng, carnitine, guarana, vitamins, minerals, herbs, protein and amino acids, creatine,
and even hornet’s saliva. See Leslie Bonci, “Energy” Drinks: Help, Harm or Hype?, Gatorade Sports Science Institute,
15 Sports Science Exchange 1, 2-3 (2002).
8people in the U.S. were taking dietary supplements between 1988 and 1994.”57 Among these users, females
were more likely to use dietary supplement than males (44% compared to 35%),58 and children age one to
ﬁve were among the largest users of dietary supplements.59 Further, among adults age twenty and older,
dietary supplement use tended to increase with age.60 Educational level and total family income were both
positively related to dietary supplement use,61 and among regions of the country, people in the West were
more likely (by at 10% margin) to take dietary supplements than people in any other region of the country.62
As to the amount of dietary supplements taken, just over two-thirds of dietary supplements users took only
one supplement and of those single users, 46% took a vitamin or mineral combination product.63 Overall
what can be said of this and other similar studies is that “dietary supplement use is more common among
older adults, women, white people, people living in the West, and those with higher incomes and levels of
education.”64
III. UNITED STATES REGULATION OF DIETARY SUPPLEMENTS
With this general background on dietary supplements in mind, this section now turns to a brief review of
the history of notable dietary supplement regulation in the United States with a focus on the DSHEA and
57DHHS Dietary Supplement Use, supra note 52, at 6. The study targeted the U.S. population of at least two months of age.
Id. at 1.
58Id. at 3.
59See id. at 3-4. Use ranged from 42% to 51%. Id. at 3.
60Id. at 3-4. Females age ﬁfty and older had the highest percentage of dietary supplement use at over 55%. See id. at 4.
61Id. at 4.
62Id.
63Id. at 5. Generally, 47% of all dietary supplement users took a vitamin or mineral combination product. Id. Other heavily
used supplements included “lecithin, garlic, ginseng, ﬁber, amino acids, protein drinks, and other performance-enhancing or
body-building formulas.” Id. at 7.
64Id. at 6. It should be noted that this study ended just as the federal government enacted the DSHEA. The study
noted that the prevalence of dietary supplement use could change with passage of the DSHEA, as more scientiﬁc evidence
accumulates supporting dietary supplement use, and as attitudes towards alternative medicine shift. Id. at 7. The ability of
dietary supplement labels to now carry a variety of health claims (unqualiﬁed or qualiﬁed) certainly has had an impact on the
prevalence of use. For more about dietary supplement health claims, see discussion infra Part III.C.5.
9post-DSHEA regulation and other activity.65
A. Pre-DSHEA Regulation
Regulation of dietary supplements is not a new phenomenon, and the DSHEA, while the most comprehensive
legislation addressing dietary supplements, was not the ﬁrst such legislation on the subject. The major pieces
of legislation addressing dietary supplements prior to the DSHEA were the Food, Drug, and Cosmetic Act
of 1938 (“FDCA”),66 the 1976 addition of section 411 to the FDCA known as the Proxmire Amendment,67
and the Dietary Supplement Act of 1992 (“DSA”).68
1. The FDCA
The FDCA made the ﬁrst legislative reference to dietary supplements. Speciﬁcally, section 403 of the FDCA
(now codiﬁed at 21 U. S. C. § 343(j)) referenced food for special dietary use.69 Further, dietary supplements
were included in the category of food in section 201(f) of the FDCA (now codiﬁed at 21 U. S. C. § 321(f).70
The FDCA also included new provisions regarding drugs, and the FDA quickly utilized these provisions to
65This review is not meant to be comprehensive. It focuses on notable dietary supplement statutory, regulatory, and industry
activity in order to convey an accurate record of dietary supplement regulation in the United States.
66Pub. L. No. 75-717, 52 Stat. 1040 (1938) (codiﬁed as amended at 21 U. S. C. § 301 et seq.).
67Pub. L. No. 94-278, 90 Stat. 401 (1976) (codiﬁed at 21 U. S. C. § 350).
68Pub. L. No. 102-571, 106 Stat. 4491 (1992).
69This provision provided that a food for special dietary use would be considered misbranded unless its “label bears such
information concerning its vitamin, mineral, and other dietary properties as the Secretary determines to be, and by regulations
prescribes as, necessary in order fully to inform purchasers as to its value for such uses.” 21 U. S. C. § 343(j). “Secretary,” here
and in all other references in the paper, refers to the Secretary of Health and Human Services. See 21 U. S. C. § 321(d).
70This section deﬁned food as “(1) articles used for food or drink for man or other animals, (2) chewing gum, and (3)
articles used for components of any such article.” Dietary supplements thus would have fallen under 21 U. S. C. § 321(f)(3);
however, under the FDCA a dietary supplement would also have been considered a food additive unless it was a substance that
was Generally Recognized as Safe (“GRAS”), or it had prior sanctioned status. James L. Vetter, Ph.D, Food Laws and
Regulations 153 (1996). Thus, if the dietary supplement was not GRAS or did not have prior sanctioned status, it would
have had to comply with the food additive provisions of the FDCA. See discussion infra Part III.B.2 on dietary supplements,
GRAS, and food additive provisions under the DSHEA.
10sweep certain food products, including certain dietary supplements, under these more stringent drug provi-
sions.71 Several cases during this time hinged on the claims made on the label of such dietary supplements
or the literature accompanying them.72
In the decades following enactment of the FDCA, the FDA passed several regulations pertaining to dietary
supplements. In 1941 the FDA promulgated the ﬁrst recommended daily allowance (“RDA”) regulations
for vitamin and mineral supplements and other foods for special dietary use containing added vitamins or
minerals.73 In 1962 the FDA published a proposed notice that “only those nutrients recognized by ‘competent
authorities’ as essential and of signiﬁcant human value could be oﬀered for sale.”74 Due to heavy pressure by
the dietary supplement industry, this proposal never went into eﬀect.75 New regulations concerning labeling
and content of special dietary food products were proposed in 196676 and were promulgated in ﬁnal form in
1973.77 These regulations classiﬁed most vitamins and minerals as drugs if they exceeded certain levels of
potency (based on RDAs) and also limited the sale of vitamin and mineral combination products.78
2. The Proxmire Amendment
Stemming from FDA action in the 1960s and early 1970s concerning dietary supplement vitamin and mineral
71I. Scott Bass & Anthony L. Young, Dietary Supplement Health and Education Act: A Legislative History and
Analysis 9 (1996).
72See id. at 9-11 (contains a discussion of these cases).
736 Fed. Reg. 5921-5926 (1941). See Commission on Dietary Supplement Labels, Report of the Commission on
Dietary Supplement Labels (Final Report 1997) 11 [hereinafter CDSL Report]. The regulations placed no limit on the
amount or type of nutrients that could be included in such supplements. CDSL Report supra.
74Bass, supra note 71, at 11 (citing 27 Fed. Reg. 5815, 5817 (June 20, 1962)).
75Id. at 11.
7631 Fed. Reg. 8521, 8526 (June 18, 1966).
7738 Fed. Reg. 20,730, 20,732 (Aug. 2, 1973). The FDA proposed that all vitamin and mineral supplements bear the
following disclaimer: “[v]itamins and minerals are supplied in abundant amounts by commonly available foods. Except for
persons with special medical needs, there is no scientiﬁc basis for recommending routine use of dietary supplements.” 31 Fed.
Reg. 15,730-15,736 (1966); see CDSL Report, supra note 73, at 11. This proposed rule was not included in the ﬁnal rulemaking.
In addition, the ﬁnal rulemaking was subject to much FDA and court revision and was ﬁnally revoked in its entirety. See CDSL
Report, supra note 73, at 12.
7838 Fed. Reg. 20,730, 20,732 (Aug. 2, 1973).
11potency, Congress took action in 1976. Unsatisﬁed with FDA regulations regarding vitamin and mineral
potency, Congress responded with the Proxmire Amendment.79 The Proxmire Amendment added section
411 to the FDCA (now codiﬁed at 21 U. S. C. § 350) and negated the FDA’s 1973 regulations concerning
vitamin and mineral potency. The Proxmire Amendment prohibited the FDA from placing maximum limits
of potency on vitamins or minerals within a food,80 invalidated the FDA’s authority to classify a vitamin
or mineral as a drug based on potency,81 and permitted vitamins and minerals to be sold in many forms,
including combinations, within a food.82 The eﬀect of the Proxmire Amendment was to limit the FDA’s
authority to regulate dietary supplements, at least when they contained vitamins or minerals.83
After the Proxmire Amendment, the FDA mostly abandoned its eﬀorts to regulate dietary supplements
under FDCA drug provisions and instead turned to FDCA food additive provisions.84 The FDA’s theory
was that dietary supplements could be attacked as unsafe food additives. By 1992, U.S. courts of appeal
rejected this theory at least regarding non-combination dietary supplements.85
3. The DSA
The next major governmental action regarding dietary supplements came when Congress passed the Nutrition
79Pub. L. No. 94-278, 90 Stat. 401 (1976) (codiﬁed at 21 U. S. C. § 350). In an eight month span in 1973 approximately
seventy bills were introduced in Congress seeking to limit the FDA’s regulation of vitamin and mineral potency. Bass, supra
note 71, at 12. The Proxmire Amendment was the ﬁnal result.
80Pub. L. No. 94-278, 90 Stat. 401 (1976) (codiﬁed at 21 U. S. C. § 350(a)(1)(A)). For purposes of 21 U. S. C. § 350, the
term food means “food for humans which is a food for special dietary use which is or contains any natural or synthetic vitamin
or mineral, and which is intended for ingestion in tablet, capsule, powder, softgel, gelcap, or liquid form, or if not intended for
ingestion in such a form, is not represented as conventional food and is not represented for use as a sole item of a meal or of
the diet.” 21 U. S. C. § 350(c)(1) (as amended by the DSHEA).
81Pub. L. No. 94-278, 90 Stat. 401 (1976) (codiﬁed at 21 U. S. C. § 350(a)(1)(B)).
82Id. (codiﬁed at 21 U. S. C. § 350(a)(1)(C)).
83After the Proxmire Amendment, no formal dietary supplement labeling provisions were in eﬀect until 1994. CDSL Report,
supra note 73 at 12. However, most dietary supplement manufactures informally followed the FDA’s 1973 regulations. Id.
84The statutory provision regarding food additives is 21 U. S. C. § 348. Basically, the FDCA requires premarket approval for
food additives that are not prior sanctioned, GRAS, or the subject of a food additive regulation.
85See United States v. Two Plastic Drums, 985 F.2d 814 (7th Cir. 1993); United States v. 29 Cartons, 987 F.2d 33 (1st Cir.
1993). Such non-combination dietary supplements thus were considered conventional food not subject to the food additives
provision. However, the FDA and some courts then took the position that dietary supplements, except vitamins and minerals
with a recognized nutritional value, were not considered conventional food. See Nutrilab v. Schweiker, 713 F.2d 335 (7th Cir.
1983); American Health Prod. Co. v. Hayes, 744, F.2d 912 (2d Cir. 1984); Bass, supra note 71, at 15.
12Labeling and Education Act of 1990 (“NLEA”).86 The NLEA provided foods, including dietary supplements,
to bear nutritional labeling.87 Further, the NLEA created a health claim approval system for the FDA
including the availability of separate procedures for dietary supplement health claims.88 However, the FDA
failed to implement any separate NLEA health claim procedures for dietary supplements except to a very
limited extent.89
The dietary supplement provisions of the NLEA were to be implemented by the FDA through publication of
proposed and ﬁnal rules, but as the FDA carried out this implementation,90 Congress passed the DSA. The
DSA instituted a one-year moratorium on implementation of dietary supplement labeling under the NLEA
with certain exceptions for health claims. 91 New proposed regulations covering dietary supplement labeling
were to be issued by June 15, 1993 with ﬁnal regulations due by the end of that year.92 While the FDA
worked to comply with these dates,93 Congress passed the DSHEA, drastically reshaping dietary supplement
regulation.
B. The Dietary Supplement Health and Education Act of 1994
Due in part to “the importance of nutrition and the beneﬁts of dietary supplements to health promotion and
86Pub. L. No. 101-535, 104 Stat. 2352 (1990) (codiﬁed in scattered section of 21 U. S. C.).
87Id. (codiﬁed at 21 U. S. C. § 343).
88Id. (codiﬁed at 21 U. S. C. § 343(r); Bass, supra note 71, at 15.
89Bass, supra note 71, at 15.
90For example, the FDA published proposed health claim regulations for dietary supplements in 1991. 56 Fed. Reg. 60,537
(Nov. 27, 1991).
91Pub. L. No. 102-571, § 202, 106 Stat. 4491 (1992).
92Id.
93The FDA issued an advance notice of proposed rulemaking concerning dietary supplement in June 1993. 58 Fed. Reg.
33,690 (June 18, 1993).
13disease prevention” and the increasing reliance of consumers on dietary supplements, 94 Congress passed the
DSHEA in 1994.95 The DSHEA created a new structure for regulation of dietary supplements by making
dietary supplements a new category of regulation within the framework of food and apart from drugs.
This was a drastic departure from previous decades of regulation. The DSHEA enacted the following main
provisions: (1) deﬁnitions of dietary supplements and dietary ingredients;96 (2) dietary supplement safety
provisions;97 (3) certain dietary supplement labeling exemptions;98 (4) statements of nutritional support for
dietary supplements;99 (5) dietary supplement labeling requirements;100 (6) regulations pertaining to new
dietary ingredients;101 (7) dietary supplement good manufacturing practices;102 (8) revocation of the FDA’s
advance notice of proposed rulemaking under the DSA;103 (9) establishment of a Commission on Dietary
Supplement Labels;104 and (10) establishment of the Oﬃce of Dietary Supplements.105
1. Dietary Supplement Deﬁnitions
The DSHEA deﬁned dietary supplements as food, 106 thus ending previous decades of controversy over
whether dietary supplements should be ﬁt into the existing food or drug frameworks. Speciﬁcally, the
94Pub. L. No. 103-417, § 2, 108 Stat. 4325 (1994).
95Pub. L. No. 103-417, 108 Stat. 4325 (1994) (codiﬁed as amended in scattered sections of 21 U. S. C.).
96Id. § 3 (codiﬁed at 21 U. S. C. §§ 321(ﬀ), 321(s)(6), 350(c)(1)(B)). The DSHEA also amended the deﬁnition of drug. Id.
at § 10 (codiﬁed at 21 U. S. C. § 321(g)(1)).
97Id. § 4 (codiﬁed at 21 U. S. C § 342(f)).
98Id. § 5 (codiﬁed at 21 U. S. C. § 343-2).
99Id. § 6 (codiﬁed at 21 U. S. C. § 343(r)(6)).
100Id. § 7 (codiﬁed at 21 U. S. C. §§ 343(s), 343(q)(5)(F), 343(r)(2)(F), 350(b)(2)); see also id. at § 10 (codiﬁed at 21 U. S.
C. § 343(s)).
101Id. § 8 (codiﬁed at 21 U. S. C. § 350b).
102Id. § 9 (codiﬁed at 21 U. S. C. § 342(g)).
103Id. § 11.
104Id. § 12.
105Id. § 13 (codiﬁed at 42 U. S. C. § 287c-11).
106Id. § 3 (codiﬁed at 21 U. S. C. § 321(ﬀ)). This deﬁnition does not apply for purposes of 21 U. S. C. §321(g) (the FDCA
deﬁnition of drug). This preserved the FDA’s ability to deem a dietary supplement a drug if the dietary supplement makes
certain claims. Certain dietary supplements can also be considered drugs under 21 U. S. C. § 321(ﬀ)(3). Dietary supplements
are excluded from the deﬁnition of drugs based on certain health or structure/function claims made on the label in compliance
with other sections of the FDCA. 21 U. S. C. §321(g)(1)(D).
14DSHEA created a new category of food and then deﬁned this category by the inclusion of the speciﬁc
dietary ingredients of vitamins, minerals, herbs or botanicals, amino acids, any substances consumed to
supplement the diet, or concentrates, metabolites, constituents, extracts, or combinations thereof.107 The
DSHEA also stated that dietary supplements must be intended for ingestion in tablet, capsule, powder, soft
gel, or liquid form.108 Further, if the dietary supplement is not intended for ingestion in such form, it must
not be represented as conventional food and must not be represented as meal replacement.109 Further, the
dietary supplement, no matter the form, must not be represented for use as conventional food and must not
be represented as meal replacement.110 Additionally all dietary supplements must be labeled as a dietary
supplement.111
The signiﬁcance of the new deﬁnitions for dietary supplements cannot be understated. These provisions
mean that dietary supplements, like all other foods, are classiﬁed based on the intended use of such products
as demonstrated by label claims, advertising, or product statements.112 Even though the DSHEA speciﬁes
certain types of dietary supplements and the forms such supplements must take, the DSHEA allows dietary
supplements to be sold in conventional food form so long as they are not represented as conventional food
or as meal replacement and so long as they are labeled as dietary supplements.113
The DSHEA also took the monumental step of excluding dietary supplements and dietary ingredients in-
107Pub. L. No. 103-417, § 3 (codiﬁed at 21 U. S. C. § 321(ﬀ)); see supra Part II.A for a discussion of types of dietary
supplements.
108Id. (codiﬁed at 21 U. S. C. §§ 321(ﬀ)(2)(A)(i), 350(c)(1)(B)(i)).
109Id. (codiﬁed at 21 U. S. C. §§ 321(ﬀ)(2)(A)(ii), 350(c)(1)(B)(ii)).
110Id. (codiﬁed at 21 U. S. C. § 321(ﬀ)(2)(B)).
111Id. (codiﬁed at 21 U. S. C. § 321(ﬀ)(2)(C)).
112See Dentali, supra note 13, at 89.
11321 U. S. C. §§ 321(ﬀ)(2)(B)-(C), 350(c)(1)(B)(ii).
15tended for use in dietary supplements from the deﬁnition of food additives,114 thus clearing up decades of
controversy on that subject.
The exclusion of dietary supplements from the FDCA food additive provisions also cannot be understated.
Because dietary supplements are now excluded from the FDCA food additive provisions, dietary supplements
cannot be deemed adulterated under food additive provisions of the FDCA. All dietary supplements thus
bypass the need to receive speciﬁc approval from the FDA for use as food additives.115 Dietary supplements
also bypass the need to be Generally Recognized as Safe (“GRAS”) by the FDA or the food industry.116
And notably, by virtue of being excluded from the deﬁnition of food additives, dietary supplements do not
have to comply with the DeLaney Clause prohibiting the FDA from approving food additives that have been
“found to induce cancer when ingested by man or animal.”117
114Id. (codiﬁed at 21 U. S. C. § 321(s)(6)).
115Food additive provisions of the FDCA are codiﬁed at 21 U. S. C. § 342. New dietary ingredients, however, must be approved
by the FDA otherwise the dietary supplement will be considered adulterated. See discussion infra Part III.B.6. As to the food
additive provisions, the process avoided is an onerous one. A brief account of the food additive process is as follows: the dietary
supplement manufacturer must (1) ﬁle a food additive petition, (2) conduct scientiﬁc data review regarding the food additive,
and (3) fulﬁll criteria of the FDA. George A. Burdock, The GRAS Process, Food Technology, May 2003, at 17. The
FDA must then (1) issue a proposed rule regarding the food additive petition for notice and comment and (2) issue a ﬁnal rule
regarding the food additive petition in the Federal Register. Burdock, supra.
116Food additives must either be GRAS or have prior sanctioned status by the FDA from before 1958, otherwise such ingredients
are considered food additives and subject to food additive provisions. See Food Additives Amendment of 1958, Pub. L. No.
85-929, 72 Stat. 1784 (1958) (codiﬁed at 21 U. S. C. §§ 342(a)(2)(C), 348, 321(s)). To have prior sanctioned status, the food
ingredient could not have been a drug or herbal remedy and must have been used by a signiﬁcant number of people before
1958. Burdock, supra note 115. If a food ingredient is GRAS for its intended use, then it may be used without seeking speciﬁc
approval from the FDA. However, for an ingredient to be GRAS, it must have been found safe through a series of scientiﬁc
tests and information. Speciﬁcally, for a substance to be GRAS
“there must be reasonable certainty in the minds of scientist that is it not harmful under its conditions of intended use; the
data and information to establish this conclusion must be publicly available; and there must be a basis to conclude that there
is consensus among qualiﬁed experts about the safety of the substance for its intended use.”
Anthony A. Anscombe, Regulating Botanicals in Food, Food Technology, Jan. 2003, at 18. This procedure is, like the
food additive procedures, an onerous one. The basic framework is as follows: the dietary supplement manufacturer must (1)
have a well prepared and researched substance, (2) have a technical use and purpose for the substance, (3) have documentation
regarding to what the substance is to be added and at what levels, (4) review the published literature and data concerning
the substance, (5) develop any needed data, (6) compile all of this information and data into a GRAS monograph, (7) have
the GRAS monograph reviewed by an independent expert panel which must produce a consensus statement regarding the
GRAS status of the substance, and (8) optionally notify the FDA. James T. Heimbach, GRAS Determination: A Short Guide,
Prepared Foods, Jan. 2003, 123, 123-129.
11721 U. S. C. § 348(c)(3)(A). Dietary supplements containing color additives must still comply with the DeLaney Clause. 21
U. S. C. § 379e(b)(5)(B)(i).
16The new dietary supplement deﬁnition and the exclusion of dietary supplements from food additive provi-
sions mean that the manner in which a product’s intended use (conventional food versus dietary supplement)
has an enormous impact on the regulatory process. For example, the DSHEA, under the new dietary sup-
plement provisions, grandfathered in many botanicals that do not have to undergo a new dietary ingredient
procedure.118 These botanicals thus may be used in dietary supplements without regulatory hassle; how-
ever, many of these same botanicals were not grandfathered in by the Food Additives Amendment of 1958
and thus would either have to be GRAS or undergo the onerous food additive approval process. Thus, a
company wishing to introduce such a botanical could save signiﬁcant time and money by introducing the
botanical as a dietary supplement rather than a conventional food or ingredient in a conventional food.119
However, dietary supplement procedures are not always the easier approach. For example, McNeil Consumer
Healthcare sought to introduce Benecol, a canola oil margarine substance that contains cholesterol-lowering
herbals or botanicals (speciﬁcally sitostanol esters), into the U.S. market as a dietary supplement.120 McNeil
ﬁgured this would present the lowest regulatory hurdles; however, the FDA rejected Benecol as a dietary
supplement. 121 The chief reason for rejection was that Benecol was represented as a conventional food.122
The FDA further held that the sitostanol esters were unapproved food additives and not GRAS, though
McNeil was able to later demonstrate GRAS status and Benecol was approved as a conventional food.123
An additional example demonstrates the malleability of the dietary supplement/conventional food distinc-
tion. The FDA and the Herbal Products Association have recently been in disagreement over whether juice
118Pub. L. No. 103-417, § 8 (codiﬁed at 21 U. S. C. § 350b); Dentali, supra note 13, at 92.
119This is particularly true because botanicals have not generally undergone large scale safety studies or accumulated other
relevant scientiﬁc data which would be useful fro GRAS determination of the food additive approval process. Anscombe, supra
note 116, at 17.
120Dentali, supra note 13, at 92.
121Id.
122The statement of identity listed Benecol as a butter or margarine replacement that would help manage cholesterol levels
naturally through food consumption. Id.
123Id. As an additional example, The Hain Foods Group, Inc., tried to introduce a line of soups containing Echinacea and St.
John’s Wart as dietary supplements. Id. The FDA rejected this use stating that labeling which contained the word “soup,”
pictures of soup, and references to conventional foods found in soup served to represent the product as conventional food.
Id. Further, the FDA stated that both Echinacea and St. John’s Wart were unapproved food additives that had yet to be
demonstrated GRAS. Id.
17beverages including herbal ingredients may be represented as dietary supplements. In 2000 and 2001 the
FDA sent warning letters to several juice manufactures alleging that the presence of certain herbal ingredients
in their juice beverages constituted adulteration.124 These juice beverages were marketed as conventional
foods and thus the FDA treated the herbal ingredients in the beverages as unapproved food additives.125
The FDA did acknowledge, however, that dietary supplements could be marketed in beverage form similar
to conventional food so long as the labeling was accurate and the dietary supplement was not represented
for use as conventional food.126
2. Dietary Supplement Safety
Because under the DSHEA dietary supplements are considered food not subject to food additive provisions,
dietary supplements are generally considered safe under the FDCA unless proven otherwise by the FDA.
To prove that a conventional food is unsafe, the FDA must follow the statutory adulteration provisions.127
However, the DSHEA created new standards by which to judge dietary supplement safety.128 Under the
DSHEA, a dietary supplement (or any food containing a dietary ingredient) is deemed adulterated if any
one of four conditions is met. First, a dietary supplement is deemed adulterated if it “presents a signiﬁcant
or unreasonable risk of illness or injury under – (i) conditions of use recommended or suggested in labeling,
or (ii) if no conditions of use are suggested or recommended in the labeling, under ordinary conditions of
use.”129 Second, a dietary supplement is deemed adulterated if it “is a new dietary ingredient for which there
124Id. at 94.
125Id.
126Id. Thus, the FDA has allowed calcium based dietary supplements to be sold as confectionary “chews.” Id. In general
though, the FDA is of the opinion that standardized food beverage names and terms like “spring water,” “orange juice,” “drink”
or “beverage” cannot appear on the label of a dietary supplement. Id.
12721 U. S. C. § 342.
128Pub. L. No. 103-417, § 4 (codiﬁed at 21 U. S. C. § 342(f)).
12921 U. S. C. § 342(f)(1)(A).
18is inadequate information to provide reasonable assurance that such ingredient does not present a signiﬁcant
or unreasonable risk of illness or injury.”130 Third, a dietary supplement is deemed adulterated if it “pose[s]
an imminent hazard to public health or safety.”131 Finally, a dietary supplement is deemed adulterated if
it meets a conventional food adulteration standard in the FDCA “under the conditions of use recommended
or suggested in the labeling of such dietary supplement.”132
The DSHEA exemption of dietary supplements from all but one conventional food adulteration standard in
the FDCA was a monumental change. Before the DSHEA, dietary supplements and dietary ingredients were
held to all the conventional food adulteration standards under 21 U. S. C. § 342. This meant that before
the DSHEA, a dietary supplement was deemed adulterated if
13021 U. S. C. § 342(f)(1)(B).
13121 U. S. C. § 342(f)(1)(C).
13221 U. S. C. § 342(f)(1)(D). Speciﬁcally, the dietary supplement must meet the adulteration standard under 21 U. S. C. §
342(a)(1). Section 342(a)(1) states that a food is deemed adulterated “[i]f it bears or contains any poisonous or deleterious
substance which may render it injurious to health; but in case the substance is not an added substance such food shall not be
considered adulterated under this clause if the quantity of such substance in such food does not ordinarily render it injurious
to health.”
19(1) it bore or contained “any poisonous or deleterious substance which... [could have] render[ed] it
injurious to health,”133
(2) in the case of a dietary supplement that contained no added substances (that is, it was not
considered a combination product or it contained only naturally occurring ingredients), if the amount
of such substance was considered unsafe within the meaning of other statutory language,134
(3) it bore or contained a “pesticide chemical residue that [wa]s unsafe” within the meaning of other
statutory language135
(4) it bore or contained a food additive that was unsafe within the meaning of the Food Additive
Amendment of 1958,136
(5) its composition or packaging met certain ﬁlth standards,137
(6) it was the product of a diseased animal or of an animal that had died other than by slaughter,138
(7) its container included “any poisonous or deleterious substance which... [could have] render[ed]
the contents injurious to health,”139
(8) it had been intentionally exposed to radiation not approved by other statutory language,140
(9) it had been adulterated in an economic sense,141
(10) it bore or contained a color additive deemed unsafe under other statutory language,142 or
(11) it met certain special confectionary or oleomargarine adulteration provisions.143
But after the DSHEA, all of these provisions (save for those listed in (1) and (2) above) were wiped clean
and replaced with more limited provisions.144 Combined with the exclusion of dietary supplements from
144Even though the adulteration provisions under 21 U. S. C. § 342(a)(1) are applied to dietary supplements, they have been
narrowed for dietary supplements by 21 U. S. C. § 342(f)(1)(D) too look only at recommended or suggested conditions of use.
20food additive provisions, the dietary supplement industry faced vastly fewer regulatory hurdles than faced
with conventional food.
The DSHEA went even further in its revisions of dietary supplement safety by placing the burden of proof
on the government to demonstrate that a dietary supplement is adulterated.145 No longer did dietary
supplement manufactures have to prove that a supplement was safe, rather the FDA had to prove the dietary
supplement unsafe. This brought dietary supplement safety enforcement in line with the conventional foods,
which are presumed to be safe unless the FDA proves otherwise, rather than drugs, which must be proven
by manufacturers to be safe and eﬃcacious. Further, the DSHEA laid out certain legal procedures that were
to be followed concerning dietary supplement safety enforcement, in eﬀect removing some FDA power over
administrative review of dietary supplements.146
3. Dietary Supplement Labeling Exemptions
The DSHEA made clear what did and did not constitute labeling for a dietary supplement. Under the
DSHEA,
[a] publication, including an article, a chapter in a book, or an oﬃcial abstract of a
145Pub. L. No. 103-417, § 4 (codiﬁed at 21 U. S. C. § 342(f)(1)).
146Speciﬁcally, when in court on any issue under 21 U. S. C. § 342(f)(1), such issue is to be decided de novo by the court
rather than by deferring to FDA interpretation. Id. Additionally, before the government takes action in the form of a civil
proceeding concerning dietary supplements under 21 U. S. C. § 342(f)(1)(A), the adverse party must receive proper notice and
an opportunity to be heard. 21 U. S. C. § 342(f)(2).
21peer-reviewed scientiﬁc publication that appears in an article and was prepared by the author or the
editors of the publication, which is reprinted in its entirety, shall not be deﬁned as labeling when
used in connection with the sale of a dietary
supplement to consumers when it–
(1) is not false or misleading;
(2) does not promote a particular manufacturer or brand of a dietary supplement;
(3) is displayed or presented, or is displayed or presented with other such items on the same subject
matter, so as to present a balanced view of the available scientiﬁc information on a dietary supple-
ment;
(4) if displayed in an establishment, is physically separate from the dietary supplements; and
(5) does not have appended to it any information by sticker or any other method.147
This section cleared up years of prior FDA regulations regarding which types of publications carried in
stores selling dietary supplements could be considered labeling under the FDCA and thus subject to labeling
regulation.148 Speciﬁcally, this section limited the FDA’s ability to regulate books and other publications as
dietary supplement labeling by deﬁning the exact conditions needed to avoid being considered labeling. In
addition, the DSHEA made clear the right of a retailer or wholesaler of dietary supplements to sell books or
other publications as part of their business regardless of the new DSHEA labeling exemptions.149 Finally,
the DSHEA put the burden of proof on the government concerning any proceeding brought under the new
DSHEA labeling exemptions.150 Thus, as with the exclusion of dietary supplements from food additive
provisions, deﬁnition as drugs, and many of the conventional food adulteration provisions, the trend of
148Speciﬁcally, 21 U. S. C. § 321(m) states that “[t]he term ‘labeling’ means all labels and other written, printed, or graphic
matter (1) upon any article or any of its containers or wrappers, or (2) accompanying such article.” If the term “labeling”
applies than the labeling sections of the FDA apply. See, e.g., 21 U. S. C. §§ 343, 350. The FDA had used 21 U. S. C. § 321(m)
and accompanying labeling provisions of the FDCA to restrict books and other publications sold in stores also selling dietary
supplements. For a discussion of this prior FDA activity, see Bass, supra note 71, at 49-50. Brieﬂy, in the decades before the
DSHEA, courts, including the U.S. Supreme Court, had upheld the FDA’s broad reading of what constituted labeling under
21 U. S. C. § 321(m). Bass, supra note 71, at 49.
149Pub. L. No. 103-417, § 5 (codiﬁed at 21 U. S. C. § 343-2(b)).
150Id. (codiﬁed at 21 U. S. C. § 343-2(c)).
22relaxed dietary supplement regulation continued in this section.
4. Statements of Nutritional Support
The DSHEA took the signiﬁcant step of allowing dietary supplement labeling and packaging to contain
certain statements of nutritional support unavailable to conventional foods by expanding the realm of such
statements.151 Speciﬁcally, the DSHEA allowed a statement of nutritional support on the label of dietary
supplements without the dietary supplement being deemed misbranded if
the statement claims a beneﬁt related to a classical nutrient deﬁciency disease and discloses the
prevalence of such disease in the United States, describes the role of a nutrient or dietary ingredient
intended to aﬀect the structure or function in humans, characterizes the documented mechanism
by which a nutrient or dietary ingredient acts to maintain such structure or function, or describes
general well-being from consumption of a nutrient or dietary ingredient.152
Thus dietary supplements could make classical nutrient deﬁciency disease statements, claims about structure
or function, and general well-being statements (together referred to as statements of nutritional support or
structure/function claims). Even before the DSHEA, structure/function claims for nutrients in conventional
foods were excluded from the deﬁnition of a drug.153 Such claims could be made without notifying the
FDA and without being deemed drug claims if they “concerned a non-disease-related eﬀect on the structure
or function of the body and the claimed eﬀect derived from a food attribute, such as nutritive value.”154
If the claims linked a nutrient to a disease or a health-related condition (so called “health claims” rather
than structure/function claims), these were also allowed before the DSHEA but required authorization by
speciﬁc FDA regulation.155 What the DSHEA accomplished was to provide expanded safe harbor from
151This modiﬁes the NLEA amendments, Pub. L. No. 101-535, 104, Stat. 2352 (1990) (codiﬁed as amended at 21 U. S. C. §
343(r)), to the FDCA for dietary supplements.
15321 U. S. C. § 321(g)(1)(C).
15465 Fed. Reg. 999, 1001 (Jan. 6, 2000). The FDA allowed, and still allows, traditional structure/function claims (such as
“calcium builds strong bones”) to be made for conventional foods. Bass, supra note 71, at 56.
15521 U. S. C. § 343(r)(1)(B), (r)(3), (r)(5)(D). For a more detailed discussion of pre-DSHEA regulation of structure/function
23drug provision for statements of nutritional support made on dietary supplements concerning nutrients and
dietary ingredients.156 The DSHEA also ensured that complying with these statements of nutritional support
provisions would not lead to a dietary supplement being deemed a drug.157
The DSHEA also required that a manufacturer of a dietary supplement containing a statement of nutritional
support on its label must have “substantiation that such statement is truthful and not misleading.”158 And
the DSHEA further required that the label contain the following disclaimer: ”This statement has not been
evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure,
or prevent any disease.”159 Finally, the DSHEA made clear that a dietary supplement shall not “claim to
diagnose, mitigate, treat, cure, or prevent a speciﬁc disease or class of diseases.”160
5. Dietary Supplement Labeling
The DSHEA enacted signiﬁcant changes to dietary supplement labeling.161 First, the label of a dietary sup-
plement must list the name of each ingredient and the quantity of such ingredient.162 Second, the label must
claims and other health related claims, see Bass, supra note 71, at 56-58. After passage of the Food and Drug Administration
Modernization Act of 1997 (“FDAMA”), Pub. L. No. 105-115, 111 Stat. 2296 (1997) (codiﬁed at 21 U. S. C. § 343(r)), such
health claims, if based on an authoritative statement, could also be made without pre-authorization by the FDA.
156Premarket approval is not permitted nor can it be required for such claims. The Statement of Agreement to the DSHEA
speciﬁcally conﬁrms this. 140 Cong. Rec. H11179 (daily ed. Oct. 6, 1999). However, while the DSHEA provision do
not require premarket approval nutrient content claims, the FDA must be notiﬁed within thirty days of marketing a dietary
supplement making a claim under this provision. 21 U. S. C. § 343(r)(6)(C). This is a signiﬁcant departure from traditional
claims for drugs, all of which must receive prior approval from the FDA. See 21 U. S. C. § 355.
157Pub. L. No. 103-417, § 10 (codiﬁed at 21 U. S. C. § 321(g)(1)(D)). This amended the deﬁnition of drug under the FDCA.
158Id. § 6 (codiﬁed at 21 U. S. C. § 343(r)(6)(B)).
159Id. (codiﬁed at 21 U. S. C. § 343(r)(6)(C)).
160Id. This serves as a line of demarcation between dietary supplements and drugs and their respective claims.
161All dietary supplement labels were required to meet these speciﬁcations after December 31, 1996. Id. § 7.
162Id. (codiﬁed at 21 U. S. C. § 343(s)(2)). If the dietary supplement contains a proprietary blend of ingredients, then the
label need only list the total quantity of all ingredients in the blend. Id. (codiﬁed at 21 U. S. C. § 343(s)(2)(A)(ii)(II)). If
the dietary supplement contains an herbal or botanical, then the label must identity “any part of the plant from which the
ingredient is derived.” Id. (codiﬁed at 21 U. S. C. § 343(s)(2)(C)).
24bear the term “dietary supplement.”163 Finally, if the dietary supplement is “covered by the speciﬁcations
of an oﬃcial compendium,” it must meet these speciﬁcations if the dietary supplement represents that it
conforms to such speciﬁcations.164 If the dietary supplement is not covered by an oﬃcial compendium, it
must contain the identity and strength that it is represented to have,165 and it must contain the quality,
purity, and compositional speciﬁcations that it is represented to have.166
The DSHEA also amended the FDCA (as amended by the NLEA) nutritional labeling and content claims
for dietary supplements. Dietary supplements must include nutrition information “in a manner which is
appropriate for the product.”167 Speciﬁcally, ingredients present in a dietary supplement in a signiﬁcant
amount and for which there is a recommendation for daily consumption (a recommended daily intake (“RDI”)
or daily reference value (“DRV”)) must be listed ﬁrst on the nutrition label.168 More importantly, the DSHEA
then required all other dietary ingredients present to be listed in the nutrition label even if they had no RDI
or DRV.169 Before the DSHEA, the FDA did not allow such a listing.170 Further, the nutritional label must
include the quantity of each listed ingredient per serving.171 Finally, the nutrition label may include the
source of a dietary ingredient, nutrition information must precede ingredient statements on the label, and if
163Id. (codiﬁed at 21 U. S. C. § 343(s)(2)(B)). The term “dietary supplement” may be modiﬁed by the name of an included
ingredient. Id.
164Id. (codiﬁed at 21 U. S. C. § 343(s)(2)(D)). The U.S. Pharmacopoeia is an example of an oﬃcial compendium.
165Id. (codiﬁed at 21 U. S. C. § 343(s)(2)(E)(ii)(I)).
166Id. (codiﬁed at 21 U. S. C. § 343(s)(2)(E)(ii)(II)).
167Id. (codiﬁed at 21 U. S. C. § 343(q)(5)(F)).
168Id. (codiﬁed at 21 U. S. C. § 343(q)(5)(F)(i)). If such an ingredient is not present in a signiﬁcant amount, it need not
be listed. Id. This is also a change from FDA regulations for conventional food which require foods to list certain nutrition
information ingredients regardless of their presence in the food. 21 U. S. C. § 343(q)(1)(D); 21 C. F. R. § 101.9. As to
what constitutes a “signiﬁcant amount” for dietary supplement nutritional label listing, see 58 Fed. Reg. 361 (Jan. 4, 1994)
(implementing NLEA dietary supplement labeling).
169Pub. L. No. 103-417, § 7 (codiﬁed at 21 U. S. C. § 343(q)(5)(F)(i)).
170Speciﬁcally, such substances could not be included in the Nutrition Facts Box of the label. 21 C. F. R. § 101.9(c) (1995).
Conventional foods still must adhere to this rule.
171Pub. L. No. 103-417, § 7 (codiﬁed at 21 U. S. C. § 343(q)(5)(F)(ii)). This section also applied to propriety blends of
ingredients. Id.
25a dietary ingredient is listed with the nutrition information it need not also be listed with the statement of
ingredients.172
The DSHEA also made several other changes for dietary supplement nutrition labeling. First, a dietary
supplement label may contain percentage-level claims for which there is no RDI or DRV without being deemed
misbranded.173 Second, the DSHEA placed all dietary supplements within the Proxmire Amendment’s
provision that listing dietary ingredients on the label with other conventional food ingredients will not cause
a dietary supplement to be deemed misbranded so long as all ingredients are listed and proper regulations
are followed.174 Finally, the DSHEA made clear that a “dietary supplement shall not be deemed misbranded
solely because its label or labeling contains directions or conditions of use or warnings.”175
6. New Dietary Ingredients
As a tradeoﬀ for excluding dietary supplements from the onerous food additive provisions and GRAS pro-
visions of the FDCA, the DSHEA enacted speciﬁc safety provisions for substances considered new dietary
ingredients. Under the DSHEA, a new dietary ingredient is “a dietary ingredient that was not marketed in
the United States before October 15, 1994 and does not include any dietary ingredient which was marketed
in the United States before October 15, 1994.”176 Thus, all dietary supplements in use before October 15,
1994 are grandfathered in and need only meet the new, limited adulteration standards for all dietary supple-
172Id. (codiﬁed at 21 U. S. C. § 343(q)(5)(F)(iii)-(iv)).
173Id. (codiﬁed at 21 U. S. C. § 343(r)(2)(F)).
174Id. (codiﬁed at 21 U. S. C. § 350(b)).
175Id. §10 (codiﬁed at 21 U. S. C. § 343(s)).
176Id. § 8 (codiﬁed at 21 U. S. C. § 350b(c)).
26ments.177 However, a dietary supplement containing a new dietary ingredient shall be deemed adulterated
under these new adulteration standards for all dietary supplements unless “[t]he dietary supplement contains
only dietary ingredients which have been present in the food supply as an article used for food in a form in
which the food has not been chemically altered.”178 Thus, dietary supplements containing only chemically
unaltered ingredients from conventional foods are excluded from the deﬁnition of new dietary ingredient.
If the above condition is not met, a dietary supplement containing a new dietary ingredient can still avoid
being deemed adulterated if
[t]here is a history of use or other evidence of safety establishing that the dietary ingredient when
used under the conditions recommended or suggested in the labeling of the dietary supplement will
reasonably be expected to be safe and, at least 75 days before being introduced or delivered for
introduction into interstate commerce, the manufacturer or distributor of the dietary ingredient or
dietary supplement provides the Secretary with information, including any citation to published
articles, which is the basis on which the manufacturer or distributor has concluded that a dietary
supplement containing such dietary ingredient will reasonably be expected to be safe.179
With this subsection, the DSHEA enacted a notiﬁcation provision which manufactures of new dietary ingre-
dients must follow. This is a notiﬁcations provision only, and it does not require, as with drugs, premarket
approval from the FDA. Further, if a dietary supplement manufacturer does not want to follow this noti-
ﬁcation provision for new dietary ingredients, the DSHEA allows such manufacturer to, in the alternative,
petition the FDA for “issuance of an order prescribing the conditions under which a new dietary ingredient
under its intended conditions of use will reasonably be expected to be safe.”180 The Secretary must then rule
on the petition within 180 days of ﬁling.181 This enables a manufacture of a supplement containing a new
dietary ingredient to skip the notiﬁcation provision and instead seek, as one scholar terms it, “an optional
177Id. § 4 (codiﬁed at 21 U. S. C. § 342(f)).
178Id. § 8 (codiﬁed at 21 U. S. C. § 350b(a)(1)). A new use of an existing dietary supplement or an increase in the recommended
dose does not make the dietary supplement new. CDSL Report, supra note 73, at 20.
180Pub. L. No. 103-417, § 8 (codiﬁed at 21 U. S. C. § 350b(b)).
181Id. Additionally, the ruling of the Secretary on the petition is considered ﬁnal agency action. Id.
27approval scheme.”182 Seeking (and receiving) this optional approval rather than issuing a notiﬁcation would
likely eliminate the possibility of FDA action against the new dietary ingredient once marketing began.
As a note, the DSHEA provisions regarding the safety of new dietary ingredients are linked to the DSHEA
provisions of safety for all dietary supplements. Thus, like with dietary supplements in general,183 with new
dietary ingredients, the FDA bears the burden in proving adulteration.
Additionally, the DSHEA made it a prohibited act to introduce or deliver for introduction into interstate
commerce a dietary supplement that is unsafe under the new dietary ingredient provisions of the DSHEA.184
The enforcement of this new provision could be problematic because the DSHEA provisions on new dietary
ingredients do not refer to unsafe dietary supplements.185
7. Dietary Supplement Good Manufacturing Practices
The DSHEA granted the Secretary the ability to issue regulations covering good manufacturing practices
(“GMPs”) for dietary supplements.186 Such regulations may cover preparation, packaging and handling of
dietary supplements and may include expiration date labeling.187 Such regulations must “be modeled after
current good manufacturing practice regulations for food and may not impose standards for which there is
no current and generally available analytical methodology.”188
182Bass, supra note 71, at 41. Such a provision was added to appease sectors of the dietary supplement industry craving
“greater certainty regarding new dietary ingredients.” Id.
183Pub. L. No. 103-417, § 4 (codiﬁed at 21 U. S. C. § 342(f)(1)). For a more detailed discussion on the interaction of the
general DSHEA safety provisions for dietary supplements and those for new dietary ingredients, see Bass, supra note 71, at
41-42.
184Pub. L. No. 103-417, § 10 (codiﬁed at 21 U. S. C. § 331(v)).
185Bass, supra note 71, at 42.
186Pub. L. No. 103-417, § 9 (codiﬁed at 21 U. S. C. § 342(g)).
187Id. (codiﬁed at 21 U. S. C. § 342(g)(1)).
188Id. (codiﬁed at 21 U. S. C. § 342(g)(2)). Further, the Secretary must follow notice and comment rulemaking for such
288. Miscellaneous Provisions
Finally, the DSHEA enacted several other provisions. First, the DSHEA rescinded the advance notice of
proposed rulemaking concerning dietary supplements issued by the FDA in June of 1993 to comply with
the DSA.189 This avoided overlap problems between the DSA and DSHEA. Second, the DSHEA created the
Commission on Dietary Supplement Labels (“CDSL”).190 The CDSL was to be an independent executive
branch agency with seven members appointed by the President.191 The purpose of the CDSL was to issue
recommendations regarding “the regulation of label claims and statements for dietary supplements, including
the use of literature in connection with the sale of dietary supplements and procedures for the evaluation
of such claims.”192 Finally, the DSHEA created the Oﬃce of Dietary Supplements (“ODS”) to be placed
within the National Institutes of Health.193 The purpose of the ODS was to conduct, coordinate, and
assemble research regarding dietary supplements and to serve as the principal dietary supplement advisor
to the Secretary.194
C. FDA Activity Regarding Dietary Supplements Post-DSHEA
While the DSHEA enacted a signiﬁcant and detailed new framework for dietary supplements, the DSHEA
left it to the Secretary, through the FDA, to implement and ﬂesh out this new framework.195 The sections
regulations. Id.
189Id. § 11. The speciﬁc rulemaking rescinded appeared in 58 Fed. Reg. 33,690 (June 18, 1993). The FDA rescinded this
rulemaking in 59 Fed. Reg. 62,644 (Dec. 6, 1994).
190Pub. L. No. 103-417, § 12.
191Id.
192Id. Such recommendations were to be made in ﬁnal report from within two years from enactment of the DSHEA. Id. Further,
the FDA was to act on such recommendations within ninety days of issuance of the ﬁnal report and complete rulemaking within
two years of issuance of the ﬁnal report. Id.
193Id. § 13.
194Id.
195This was made all the more important by the fact that little legislative history was adopted as part of the DSHEA.
Speciﬁcally, the Statement of Agreement passed by the House and the Senate read: “This statement comprises the entire
legislative history for the Dietary Supplement Health and Education Act of 1994, S.784. It is the intent of the chief sponsors
29below explore notable details, successes, and failures of the FDA’s implementation of the DSHEA.
1. Dietary Supplement Labeling and Labeling Exemptions
The DSHEA enacted several new provisions concerning dietary supplement labeling,196 but it left most of
the work to be done by FDA implementation. Speciﬁcally, the CDSL was to ﬁrst issue a ﬁnal report on
dietary supplement labeling on which the FDA was then to act.197 The CDSL issued its ﬁnal report on
November 27, 1997.198 The CDSL ﬁnal report covered recommendations on safety, label statements, health
claims, substantiation of claims, and botanical supplements.199 As to the labeling exemptions under the
DSHEA, the CDSL ﬁnal report oﬀered guidance that the FDA undertake “proactive monitoring of practice
in this area... as resources permit and that regulatory guidance be developed if necessary.”200 The CDSL
ﬁnal report speciﬁed that providing balanced, truthful information to consumers was the primary goal and
as such the exemption should be used with care and its requirement be strictly observed.201 As to speciﬁc
labeling, the CDSL simply stated that “[t]he Commission supports the informative label format mandated
by DSHEA and urges orderly implementation of appropriate regulations.”202
of the bill ...that no other reports or statements be considered as legislative history for the bill.” 140 Cong. Rec. H11179
(daily ed. Oct. 6, 1999). The Statement of Agreement went on to list only ﬁve short, limited points to include in the legislative
history. Id.
196Pub. L. No. 103-417, §§ 3 (codiﬁed at 21 U. S. C. § 343-2), 7 (codiﬁed at 21 U. S. C. §§ 343(s), 343(q)(5)(F), 343(r)(2)(F),
350(b)(2)); 10 (codiﬁed at 21 U. S. C. § 343(s)), 12. See discussion supra Part.III.B.
197Pub. L. No. 103-417, § 12.
198CDSL Report, supra note 73.
199Id.
200Id. at xi.
201Id. at 47. For recent FDA activity regarding such third party labeling and food products including dietary supplements,
see Letter from Margaret M. Dotzel, Associate Commission for Policy, Center for Food Safety and Applied Nutrition, Food and
Drug Administration, to Daniel J. Popeo
& Paul D. Kamenar, Washington Legal Foundation (Nov. 1, 2001), available at http://www.cfsan.fda.gov/∼dms/labwww.html.
202CDSL Report, supra note 73, at 29. This response was partly shaped by the fact that at the time of issuance of the CDSL
ﬁnal report the FDA had already issued proposed and then ﬁnal regulations for dietary supplement labeling regarding identity,
nutrition, and ingredient labeling. See 60 Fed. Reg. 67,194-67,224 (Dec. 28, 1995); 62 Fed. Reg. 49,859-49,868 (Sep. 23, 1997).
30The FDA did not wait for the CDSL ﬁnal report before issuing detailed dietary supplement labeling regu-
lations under the DSHEA. In 1995, the FDA issued proposed rules regarding the statement of identity on
dietary supplement labels, speciﬁc nutrition and ingredient labeling for dietary supplements, and type-size
requirements for such labels. 203 These regulations were issued in ﬁnal form in 1997,204 and they became
eﬀective March 23, 1999.205 The regulations require that the statement of identity on a dietary supple-
ment product label must contain the term dietary supplement.206 This could be modiﬁed by dropping the
term “dietary” and substituting the name of the dietary supplement ingredient (such as “Vitamin C Sup-
plement”) or including other descriptive terms (such as “Herbal Supplement”).207 However, generic terms
(such as “Food Supplement”) are not allowed because such terms failed to identify or describe the dietary
ingredient or ingredients present in the supplement.208
The labeling regulations for dietary supplement go into much more detail (greater than can be presented
here), but a cursory glance at some of the more prominent provisions is warranted. The regulations require
that dietary supplements list the serving size, particularly by actually using the term “serving size” instead
of an alternative term like “recommended use” or “dose.”209 Also required is that all dietary supplement
labels list the fourteen nutrients mandatory for conventional food labels unless such nutrients are absent or
present in an insigniﬁcant amount.210 Further, for dietary supplements containing dietary ingredients that
20360 Fed. Reg. 67,194 (Dec. 28, 1995).
20462 Fed. Reg. 49,826 (Sep. 23, 1997) (codiﬁed in scattered sections of 21 C. F. R.).
205Id.
206Id. at 49,847 (codiﬁed at 21 C. F. R. § 101.3(g)).
207Id. at 49,827 (codiﬁed at 21 C. F. R. § 101.3(g)).
208Id. The regulations also stipulated that type-size requirements in eﬀect for conventional foods would not be altered for
dietary supplements. Id. Thus the statement of identity for dietary supplements was required to “be in a size reasonably related
to the most prominent printed matter” on the label. Id. (codiﬁed at 21 C. F. R. § 101.3(d)).
209Id. at 49,849. (codiﬁed at 21 C. F. R. § 101.36).
210See id. (codiﬁed at 21 C. F. R. § 101.36). The fourteen nutrients mandatory for conventional food labels are calories,
calories from fat, total fat, saturated fat, cholesterol, sodium, total carbohydrates, dietary ﬁber, sugars, protein, vitamin A,
31do not have an RDI or DRV, dietary supplement labels must bear a footnote stating as such,211 and the
label must list all such dietary ingredients under a heavy bar and after all listed dietary ingredient with
an RDI or DRV.212 The regulations also took the important step of requiring dietary supplement labels to
include nutrition informational in a box entitled “Supplement Facts” rather than the title “Nutrition Facts”
used on conventional foods.213 This serves to easily distinguish dietary supplements from conventional foods,
especially when dietary supplements are sold in conventional food form.
The FDA also promulgated an additional set of ﬁnal rules in 1997 that addressed certain labeling issues.214
This regulation allows a dietary supplement containing a dietary ingredient for which there is no RDI or
DRV to state the percentage level of such dietary ingredient without the need for approval from the FDA.215
This is something that is not allowed on conventional food because conventional food is forbidden to list
non-RDI or DRV nutrients on the nutrition label.
While the above 1997 ﬁnal rules took care of much of the details of the design and content of dietary sup-
plement labels, the FDA proposed additional labeling rules in 1999.216 These proposed rules stated that
dietary supplements could, in addition to listing nutritional information on a per serving basis, also list such
vitamin C, calcium, and iron. 21 C. F. R. § 101.9(c). The regulations also refuse to exempt herbal and botanical dietary
supplements from listing these fourteen nutrients if present in a signiﬁcant amount. 62 Fed. Reg. 49,828 (Sep. 23, 1997).
21162 Fed. Reg. 49,826, 49,832, 49,850 (Sep. 23, 1997) (codiﬁed at 21 C. F. R. § 101.36(b)(2)(iii)(F)).
212Id. at 49,838, 49,851-852 (codiﬁed at 21 C. F. R. § 101.36(e)(6)(ii)).
213Id. at 49,851 (codiﬁed at 21 C. F. R. § 101.36(e)(1)). Some comments to this proposed rule argued that the title
“Nutrition Facts” should be allowed for dietary supplement because the DSHEA used the term nutritional information for
dietary supplement labels, that the information provided on the dietary supplement label was at least in part nutritional
information, and that dietary supplements were marketed for their nutritional value. Id. at 49,837. The FDA rejected these
arguments in favor of facilitating consumer identiﬁcation of dietary supplements versus conventional food. Id.
21462 Fed. Reg. 49,859 (Sep. 23, 1997) (codiﬁed in scattered sections of 21 C. F. R.).
215Id. at 49,867 (codiﬁed at 21 C. F. R. § 101.13(q)(3)(ii)). The label must also list the actual amount of the dietary
supplement per serving next to the percentage level claim. Id. (codiﬁed at 21. U. S. C. § 101.13(q)(3)(ii)(A)).
21664 Fed. Reg. 1765 (Jan. 12, 1999).
32nutritional information on a per day basis.217 Further, if the dietary supplement is recommended to be taken
more than once a day, the total qualitative amount and the percent of daily value of each dietary ingredient
recommended to be taken per day must appear on the label.218 As of April 2004 the FDA has not issued a
ﬁnal rule on this point.
2. New Dietary Ingredients
As a tradeoﬀ for relaxing the adulteration regulations for dietary supplements and removing dietary sup-
plements from food additive and GRAS procedures, the DSHEA enacted special safety provisions for new
dietary ingredients.219 Included within these new safety procedures was a provision requiring the Secretary
to be notiﬁed prior to the introduction of a dietary supplement containing a new dietary ingredient.220
In 1996, the FDA issued proposed rules establishing a premarket notiﬁcation procedure for new dietary
ingredients.221 And in 1997 the FDA issued ﬁnal rules regarding new dietary ingredient premarket notiﬁ-
cation.222 These regulations apply only to a new dietary ingredient “that has not been present in the food
supply as an article used for food in a form in which the food has not been chemically altered.”223 The
notiﬁcation is to include: (1) the complete address of the manufacturer or distributor, (2) the name of the
dietary supplement, (3) a description of the dietary supplement including the level at which the new dietary
217Id.
218Id.
219Pub. L. No. 103-417, § 8 (codiﬁed at 21 U. S. C. § 350b). See discussion supra Part III.B.6.
220Id. Speciﬁcally, a dietary supplement can avoid being deemed adulterated if
[t]here is a history of use or other evidence of safety establishing that the dietary ingredient when used under the conditions
recommended or suggested in the labeling of the dietary supplement will reasonably be expected to be safe and, at least 75 days
before being introduced or delivered for introduction into interstate commerce, the manufacturer or distributor of the dietary
ingredient or dietary supplement provides the Secretary with information, including any citation to published articles, which is
the basis on which the manufacturer or distributor has concluded that a dietary supplement containing such dietary ingredient
will reasonably be expected to be safe.
Pub. L. No. 103-417, § 8 (codiﬁed at 21 U. S. C. § 350b(a)(2)).
22161 Fed. Reg. 50,774 (Sep. 27, 1996).
22262 Fed. Reg. 49,886 (Sep. 23, 1997) (codiﬁed at 21 C. F. R. § 190.6).
223Id. at 49,892 (codiﬁed at 21 C. F. R. § 190.6(a)). Premarket notiﬁcation of new dietary ingredients thus applies only to
new dietary ingredients described in section 413(a)(2) of the DSHEA. See Pub. L. No. 103-417, § 8 (codiﬁed at 350b(a)(1)).
33ingredient is present in the new dietary supplement, and (4) the conditions of recommend or suggested use.224
Further, the notiﬁcation must include the history of use or other evidence demonstrating that the dietary
supplement will reasonably be expected to be safe for its intended use.225 The regulations also prohibit
introduction of a new dietary ingredient within seventy-ﬁve days of ﬁling of the premarket notiﬁcation.226
Finally, the regulations provide that a failure of the FDA to respond to the notiﬁcation, while not baring
introduction of the dietary supplement, does not constitute approval by the FDA.227 This reinforces the
point that the DSHEA merely created a premarket notiﬁcation procedure for new dietary supplements and
not a premarket approval procedure as with drugs.
3. Nutrient Content Claims
A nutrient content claim is one that describes the level of a nutrient in a conventional food or dietary
supplement by using certain terms or compares the level of nutrients in such product to another product.228
The NLEA allowed nutrient content claims to be made for both conventional food and dietary supplements
if the FDA ﬁrst promulgated a regulation regarding such a claim.229 The DSHEA did not change this
regulatory framework. The ﬁrst FDA action post-DSHEA concerning nutrient content claims for dietary
22462 Fed. Reg. 49,886, 49,892 (Sep. 23, 1997) (codiﬁed at 21 C. F. R. § 190.6(b)). If there is no recommend or suggested
conditions of use, the notiﬁcation must include the ordinary conditions of use for the dietary supplement. Id.
225Id. Further the notiﬁcation must include a signature. Id.
226Id. (codiﬁed at 21 C. F. R. § 190.6(c)). The regulations also provide for supplemental information concerning history of
use and safety to be submitted after the initial notiﬁcation and that the FDA will not disclose the notiﬁcation submission for
ninety days. Id. (codiﬁed at 21 C. F. R. § 190.6(d)-(e)).
227Id. (codiﬁed at 21 C. F. R. § 190.6(f)). As of September 10, 2001 the FDA had received and acted on over ninety-six
notiﬁcations. Office of Nutritional Products, Labeling and Dietary Supplements, Center for Food Safety and
Applied Nutrition, Food and Drug Administration, New Dietary Ingredients in Dietary Supplements (Sep. 10,
2001), at http://www.cfsan.fda.gov/∼dms/ds-ingrd.html. Most notiﬁcations were ﬁled without comment by the FDA. Id.
228Office of Nutritional Products, Labeling, and Dietary Supplements, Center for Food Safety and Applied
Nutrition, Food and Drug Administration, Claims That Can Be Made for Conventional Foods and Dietary Sup-
plements (Sep. 2003), available at http://www.cfsan.fda.gov/∼dms/hclaims.html [hereinafter Claims].
229Pub. L. No. 101-535, 104, Stat. 2352 (1990) (codiﬁed as amended at 21 U. S. C. § 343(r)). Generally the NLEA regulation
process beings with a petition from a manufacturer. 21 C. F. R. § 101.69.
34supplements came in 1995. In that year, the FDA published proposed rules for certain nutrient content
claims for both conventional food and dietary supplements.230 Then in 1997, the FDA promulgated ﬁnal
version of these rules.231 These ﬁnal rules specify several terms that can be used to describe the nutrient
content in dietary supplements. First, while dietary supplements can list nutrition information for nutrients
that have no RDI and DRV, the regulations make clear “that the use of deﬁned nutrient content claims, such
as ‘more’ and ‘high,’ remains limited, for both conventional foods and dietary supplements, to those dietary
ingredients that have RDI’s or DRV’s.”232 Second, the regulations allow the following nutrient content
terms to be used on dietary supplement labels: (1) “high,” “rich in,” or “excellent source,”233 (2) “good
source,” “contains,” or “provides,”234 (3) “more,” “fortiﬁed,” “enriched,” or “added.”235 Third, a separate
set of regulations issued the same day allow dietary supplements to use the terms “high potency,” and
“antioxidant.”236 Finally, the FDA currently has issued proposed rules to amend sodium level regulations
in conventional foods and dietary supplements that use the term “healthy.”237
When the FDCA was amended by the Food and Drug Administration Modernization Act of 1997 (“FDAMA”),
it allowed nutrient content claims for conventional food and dietary supplements to be made by an additional
route.238 Speciﬁcally, the FDAMA allowed nutrient content claims to be made without the need for an FDA
23060 Fed. Reg. 67,176 (Dec. 28, 1995).
23162 Fed. Reg. 49,859 (Sep. 23, 1997) (codiﬁed in scattered sections of 21 C. F. R.); 62 Fed. Reg. 49,868 (Sep. 23, 1997)
(codiﬁed at 21 C. F. R. §§ 101.54, 101.50).
23262 Fed. Reg. 49,859, 49,861 (Sep. 23, 1997). However, percentage nutrient content claims for dietary ingredients with no
RDI or DRV are allowed. See discussion supra Part III.C.1.
23362 Fed. Reg. 49,859, 49,867 (codiﬁed at 21 C. F. R. § 101.54(b)). To use these terms, the dietary supplement must have
“20 percent or more of the RDI or the DRV per reference amount customarily consumed.” Id.
234Id. (codiﬁed at 21 C. F. R. § 101.54(c)). To use these terms, the dietary supplement must have “10 to 19 percent of the
RDI or the DRV per reference amount customarily consumed.” Id.
235Id. (codiﬁed at 21 C. F. R. § 101.54).
23662 Fed. Reg. 49,868, 49,880 (Sep. 23, 1997) (codiﬁed at 21 C. F. R. § 101.54(e)). For a list of more approved nutrient content
terms, see 21 C. F. R. §§ 101.13, 101.54, 101.56, 101.60-101.62; Center for Food Safety and Applied Nutrition, Food and
Drug Administration, A Food Labeling Guide, Appendix A (June 1999), available at http://www.cfsan.fda.gov/∼dms/ﬂg-
6a.html; Center for Food Safety and Applied Nutrition, Food and Drug Administration, A Food Labeling Guide,
Appendix B (June 1999), available at http://www.cfsan.fda.gov/∼dms/ﬂg-6b.html.
23768 Fed. Reg. 8163 (Feb. 20, 2003).
238Pub. L. No. 105-115, 111 Stat. 2296 (1997) (codiﬁed in scattered sections of 21 U. S. C.); see Office of La-
beling, Food and Drug Administration, Guidance for Industry: Notification of a Health Claim or Nutri-
35regulation if based upon current, published authoritative statements from certain scientiﬁc bodies.239 The
FDAMA speciﬁed premarket notiﬁcation procedures that must be met in such a case.240 If these notiﬁcation
procedures are met and the FDA does not act within the speciﬁed statutory time frame, the nutrient content
claim may be made. The FDA lists only one dietary supplement nutrient content claim made under this
provision – a 2001 petition concerning dietary supplements containing chlorine.241
4. Structure/Function Claims
Under the DSHEA, a claim is a structure/function claim if
the statement claims a beneﬁt related to a classical nutrient deﬁciency disease and discloses the
prevalence of such disease in the United States, describes the role of a nutrient or dietary ingredient
intended to aﬀect the structure or function in
ent Content Claim Based on an Authoritative Statement of a Scientific Body (June 11, 1998), available at
http://www.cfsan.fda.gov/∼dms/hclmguid.html [hereinafter Guidance Doc.].
239Pub. L. No. 105-115, 111 Stat. 2296 (1997) (codiﬁed at 21 U. S. C. § 343(r)).
240Id. (codiﬁed at 21 U. S. C. § 343(r)(2)(G)). Speciﬁcally, a nutrient content claim may be made without an FDA regulation
covering such claim if
(i) a scientiﬁc body of the United States Government with oﬃcial responsibility for public health protection or research directly
relating to human nutrition (such as the National Institutes of Health or the Centers for Disease Control and Prevention) or
the National Academy of Sciences or any of its subdivisions has published an authoritative statement, which is currently in
eﬀect, which identiﬁes the nutrient level to which the claim refers;
(ii) a person has submitted to the Secretary, at least 120 days... before the ﬁrst introduction into interstate commerce of the
food with a label containing the claim,
(I) a notice of the claim, which shall include the exact words used in the claim and shall include a concise description of the
basis upon which such person relied for determining that the requirements of subclause (i) have been satisﬁed,
(II) a copy of the statement referred to in subclause (i) upon which such person relied in making the claim, and
(III) a balanced representation of the scientiﬁc literature relating to the nutrient level to which the claim refers;
(iii) the claim and the food for which the claim is made are in compliance with [existing regulations and statutory sections
concerning labeling terms, nutrient content claims, and false and misleading claims ]... and
(iv) the claim is stated in a manner so that the claim is an accurate representation of the authoritative statement referred to in
subclause (i) and so that the claim enables the public to comprehend the information provided in the claim and to understand
the relative signiﬁcance of such information in the context of a total daily diet.
21 U. S. C. § 343(r)(2)(G).
241Center for Food Safety and Applied Nutrition, Food and Drug Administration. Nutrient Content Claims
Notification for Chlorine Containing Foods (Aug. 20, 3001), available at http://www.cfsan.fda.gov/∼dms/ﬂcholin.html.
The FDA did not choose to act within the 120 day statutory period and thus the claim was allowed to be used. Id.
36humans, characterizes the documented mechanism by which a nutrient or dietary ingredient acts to
maintain such structure or function, or describes general well-being from consumption of a nutrient
or dietary ingredient.242
The FDA allows structure/function claims to be made for conventional foods without notiﬁcation so long as
such statements are truthful, not misleading, and derive from the nutritive value of the food.243 Further such
structure/function claims for conventional foods must concern “a non-disease-related eﬀect on the structure
or function of the body and the claimed eﬀect derived from a food attribute.”244 The DSHEA preserved this
framework but enlarged the scope of structure/function claims that could be made for dietary supplements
without being considered drug claims.245 In 1995, the FDA issued proposed regulations concerning struc-
ture/function claims for dietary supplements.246 The FDA issued these regulations in ﬁnal from in 1997.247
Speciﬁcally, these regulations spell out the exact language of the disclaimer or disclaimers that must appear
on the dietary supplement label if a structure/function claim is made and the placement and size of the
disclaimer on the label.248
In 1996, the FDA issued proposed rules for the notiﬁcation and substantiation procedure under the DSHEA
for dietary supplements making structure/function claims.249 The FDA issued its ﬁnal rule pertaining to
notiﬁcation and substantiation in 1997.250 This rule provides that notiﬁcation must be made within thirty
24321 U. S. C. §§ 321(n), 343(a)(1); 62 Fed. Reg. 49,859, 49,860 (Sep. 23, 1997); Claims, supra note 228.
24465 Fed. Reg. 999, 1001 (Jan. 6, 2000).
245Pub. L. No. 103-417, § 6 (codiﬁed at 21 U. S. C. § 343(r)(6)); see discussion supra Part III.B.4. To make such claims, the
manufacturer of the dietary supplement must have substantiation of the claims, must include a disclaimer on the label that
such claims have not been evaluated by the FDA and are not intended to treat a disease, and must notify the FDA of the claim
within thirty days of introducing the product. Pub. L. No. 103-417, § 6 (codiﬁed at 21 U. S. C. § 343(r)(6)).
24660 Fed. Reg. 67,176 (Dec. 28, 1995).
24762 Fed. Reg. 49,859 (Sep. 23, 1997) (codiﬁed in scattered sections of 21 C. F. R.). The regulations make clear that
a dietary supplement may follow the previous structure/function framework for conventional foods if it qualiﬁes for the food
exemption under 21 U. S. C. § 321(g)(1)(C) unless the dietary supplement contains no nutritive value (in which case it must
comply with the DSHEA procedures). Id. at 49,863-864.
248Id. at 49,867-868 (codiﬁed at 21 C. F. R. §101.93).
24961 Fed. Reg. 50,771 (Sep. 27, 1996).
25062 Fed. Reg. 49,883 (Sep. 23, 1997) (codiﬁed at 21 C. F. R. § 101.93).
37days of introducing the dietary supplement with the structure/function claim.251 Further, the notiﬁcation
must include: (1) the name and address of the manufacturer or distributor, (2) the text of the claim made, (3)
the name of the dietary ingredient that is the subject of the claim, (4) the name of the dietary supplement,
including the brand name, on which the claim appears, and (5) a signature certifying that the manufacturer
or distributor has substantiation that the claims is truthful and not misleading. 252
In 1998, the FDA undertook the more monumental tasks of (1) deﬁning the general types of structure/function
claims that could be made on dietary supplement labels and (2) attempting to distinguish such claims from
disease or health-related condition claims – claims “that describe the relationship between a nutrient and a
disease or health related condition.”253 The FDA issued ﬁnal rules on this topic in 2000 after receiving over
235,000 comments and holding a public meeting.254 The ﬁnal rule distinguishes general structure/function
claims (which need no FDA prior approval) from disease or health-related condition claims (which need FDA
authorization, or premarket notiﬁcation under the FDAMA, or else are handled as new drug claims).255 The
ﬁnal rule promulgated three main provisions.256 First, the FDA preserved the deﬁnition of “disease or
health-related condition” in conjunction with claims made by dietary supplements.257 Second, the regula-
tions narrowed what is considered a disease of health-related condition for dietary supplement purposes:
251Id. at 49,886.
252Id.
25363 Fed. Reg. 23,624 (April 29, 1998).
25465 Fed. Reg. 1000 (Jan. 6, 2000) (codiﬁed at 21 U. S. C. § 101.93)
255Id. at 1001, 1050. The FDA noted that while it “believes that dietary supplements have potential beneﬁts for consumers,
dietary supplements labeled with unproven disease claims, i.e., those that have not met the requirements of health claim
authorization or new drug approval, can pose serious risks.” Id. For more on health claims, see discussion infra Part III.C.5.
25665 Fed. Reg. 1000, 1050 (Jan. 6, 2000) (codiﬁed at 21 C. F. R. § 101.93).
257Id. at 1000. The deﬁnition states
[d]isease or health-related condition means damage to an organ, part, structure, or system of the body such that it does not
function properly (e.g., cardiovascular disease), or a state of health leading to such dysfunctioning (e.g., hypertension); except
that diseases resulting from essential nutrient deﬁciencies (e.g., scurvy, pellagra) are not included in this deﬁnition.
21 C. F. R. § 101.14(a)(5). The regulations codiﬁed this deﬁnition for dietary supplement purposes at 21 C. F. R. § 101.93(g).
38menopause, aging, and pregnancy are not themselves diseases but... certain conditions associated
with them are diseases if they are recognizable to consumers or health professionals as abnor-
mal [and]... [c]ommon conditions associated with natural states or processes that do not cause
signiﬁcant or permanent harm will not be treated as diseases.258
Thus conditions like hot ﬂashes, hair loss due to aging, and certain types of acne are not considered diseases
and thus are eligible for dietary supplement structure/function claims.259 Finally, the ﬁnal rule allows dietary
supplement manufacturers to substantiate label claims by citing (on the label) to the title of publication
referring to a disease so long as, in the context of the whole label, such citation does not imply “that the
product may be used to diagnose, treat, mitigate, cure, or prevent disease.”260
5. Health Claims
While the DSHEA did expand the types of statements of nutritional support that could be made on dietary
supplement labels without prior approval by the FDA,261 it did not include any provisions for health-related
condition or disease claims (“health claims”) for dietary supplements. This was left to other statutes and
regulations. Health claims are claims that “describe a relationship between a food, food component, or
dietary supplement ingredient, and reducing risk of a disease or health-related condition.”262
(i) The NLEA
259Id. at 1000, 1050 (codiﬁed at 21 C. F. R. § 101.93(g)).
260Id. For a summary of structure/function regulations see Center for Food Science and Applied Nu-
trition, Small Entity Compliance Guide: Structure/Function Claims, (Jan. 9, 2002), available at
http://www.cfsan.fda.gov/∼dms/sclmguid.html.
261See discussion supra Parts III.B.4, III.C.4.
262.Claims, supra note 228; see also 21 C. F. R. § 101.14.
39One way that a health claim may appear on a dietary supplement is by following provisions under the NLEA
allowing for health claims upon approval by the FDA after careful review of scientiﬁc evidence.263
The DSHEA did not alter the NLEA framework regarding health claims for dietary supplements. In 1994,
before passage of the DSHEA, the FDA had issued ﬁnal rules on health claims for dietary supplements.264
These regulations stated that dietary supplements would be held to the same health claim standards as
conventional foods.265 Rather than enact new health claim provisions for dietary supplements, the DSHEA
appointed the CDSL to issue recommendations on such health claims.266 The FDA was then to timely
complete ﬁnal rulemaking on the CDSL recommendations or else the 1994 FDA ﬁnal regulations on dietary
supplement health claims would be rescinded.267 The CDSL issued its ﬁnal report in 1999, speciﬁcally
recommending that “[t]he process for approval of health claims as deﬁned by the NLEA should remain the
same for dietary supplements and conventional food.”268 This eﬀectively preserved the FDA’s 1994 ﬁnal
regulations on health claims and dietary supplements. Thus a dietary supplement may make a health claim
by complying with the NLEA provisions regarding health claims for conventional foods.
Under the NLEA, a health claim may be made if the FDA has issued a regulation permitting such a health
claim.269 Such regulation shall issue
263Pub. L. No. 101-535, 104, Stat. 2352 (1990) (codiﬁed as amended at 21 U. S. C. § 343(r)).
26459 Fed. Reg. 395 (Jan. 4, 1994).
265Id. The NLEA had speciﬁcally exempted dietary supplements from these new health claim provisions for conventional
foods, instead leaving it to the Secretary to promulgate regulations. Pub. L. No. 101-535, 104 Stat. 2352 (1990) (codiﬁed at
21 U. S. C. § 343(r)(5)(D)).
266Pub. L. No. 103-417, §12, 108 Stat. 4332 (1994).
267Id.
268CDSL Report, supra note 73, at 35.
269Pub. L. No. 101-535, 104, Stat. 2352 (1990) (codiﬁed as amended at 21 U. S. C. § 343(r)(3)(A)(i)). The Secretary may
issue such a regulation
40only if the Secretary determines, based on the totality of publicly available scientiﬁc evidence (in-
cluding evidence from well-designed studies conducted in a manner which is consistent with generally
recognized scientiﬁc procedures and principles), that there is signiﬁcant scientiﬁc agreement, among
experts qualiﬁed by scientiﬁc training and experience to evaluate such claims, that the claim is
supported by such evidence.270
The key phrase in this statutory language is “signiﬁcant scientiﬁc agreement.” To help manufacturers of
dietary supplements (as well as conventional foods) determine what the FDA considers to be “signiﬁcant
scientiﬁc agreement,” in 1999 the FDA issued a guidance document.271 The guidance documents states
that the “FDA’s determination on signiﬁcant scientiﬁc agreement represents the agency’s best judgment as
to whether qualiﬁed experts would likely agree that the scientiﬁc evidence supports the substance/disease
relationship that is the subject of a proposed health claim.”272
This is as strict yet objective standard designed to make “the key determination of whether a change in the
dietary intake of the substance will result in a change in a disease endpoint.”273
Under the NLEA and accompanying regulations, several health claims have been approved for use on dietary
supplement (as well as conventional food) labels.274 These range from calcium-osteoporosis claims to folate-
neural tube defects claims to plant stanols-coronary heart disease claims.275
if the food for which the claim is made does not contain, as determined by the Secretary by regulation, any nutrient in
an amount which increases to persons in the general population the risk of a disease or health-related condition which is diet
related, taking into account the signiﬁcance of the food in the total daily diet.
Id. (codiﬁed as amended at 21 U. S. C. § 343(r)(3)(A)(ii)). Generally the regulation process begins with a petition by a
manufacturer. 21 C. F. R. §§ 101.70.
271Center for Food Safety and Applied Nutrition, Food and Drug Administration, Guidance for Industry –
Significant Scientific Agreement in the Review of Health Claims for Conventional Foods and Dietary Supplements
(Dec. 22, 1999), available at http://www.cfsan.fda.gov/∼dms/ssaguide.html.
272Id.
273Id.
27421 C. F. R. §§ 101.72-101.83; Center for Food Safety and Applied Nutrition, Food and Drug Administration, A
Food Labeling Guide, Appendix C (Nov. 2000), available at http://www.cfsan.fda.gov/∼dms/ﬂg-6c.html [hereinafter Food
Label Appendix C]; see Approved Health Claims, Food Technology, Dec. 2003, at 88-89.
27521 C. F. R. §§ 101.72-101.83; Food Label Appendix C, supra note 274; see Approved Health Claims, supra note 274.
41(ii) The FDAMA and Health Claims Based on Authoritative Statements
The FDAMA provided an additional means for listing health claims on the labels of conventional foods:
use of a premarket notiﬁcation system for health claims based on an authoritative statement from certain
scientiﬁc bodies.276 Thus health claims may be made under the FDAMA without the need for premarket
approval by the FDA. However, the FDAMA did not enact this premarket notiﬁcation system for health
claims on dietary supplement labels.277
Noting that the FDAMA had created an additional health claim procedure for conventional foods but not
for dietary supplement, the FDA issued proposed rules in 1999 to equalize the health claim treatment of
dietary supplements and conventional foods.278 The FDA stated that it “believes that, for health claims,
conventional foods and dietary supplements should be subject to the same standards and procedures, in-
cluding the notiﬁcation procedure provided by FDAMA.”279 As of April 2004, the FDA has yet to issue ﬁnal
rules on this subject.280
(iii) Qualiﬁed Health Claims
276Pub. L. No. 105-115, 111 Stat. 2296 (1997) (codiﬁed at 21 U. S. C. § 343(r)(3)). The FDAMA enacted the same pre-
market notiﬁcation scheme for nutrient content claims based on authoritative statements. For a listing of these pre-notiﬁcation
procedures see discussion supra Part III.C.3, especially note 240.
277See Pub. L. No. 105-115, 111 Stat. 2296 (1997) (codiﬁed at 21 U. S. C. § 343(r)(3)). The FDAMA is limited to conventional
foods only here.
27864 Fed. Reg. 3250 (Jan. 21, 1999).
279Id. at 3251.
280The proposed rules do, however, point to a guidance document. Id. at 3252; see Guidance Doc., supra note 238. Ad-
ditionally, currently three health claims based on authoritative statements are in use for conventional foods (but not dietary
supplements). See Food Label Appendix C, supra note 274; Center for Food Safety and Applied Nutrition, Food and
Drug Administration, Health Claim Notification for Whole Grain Foods with Moderate Fat Content (Dec. 9,
2000), available at http://www.cfsan.fda.gov/∼dms/ﬂgrain2.html; see also Approved Health Claims, supra note 274.
42In 1999, a U.S. Court of Appeals ruled that under the commercial speech doctrine of the First Amendment,
the FDA could not reject health claims for dietary supplements based on their potential to mislead unless
the FDA found that no disclaimer would eliminate such potential deception.281 Thus, the opinion meant
that the FDA could not insist on the signiﬁcant scientiﬁc standard under the NLEA as the sole means for
approving health claims in dietary supplement. Such health claims that do not meet the NLEA signiﬁcant
scientiﬁc standard are referred to by the FDA as qualiﬁed health claims.282
In response to the court decision, the FDA issued a notice in 2000 delineating circumstances in which the
agency might exercise enforcement discretion for a qualiﬁed health claim in dietary supplement labeling.283
This notice was followed by a FDA notice in 2002 of forthcoming interim industry guidance for making
qualiﬁed health claims for dietary supplements.284 This notice further speciﬁed that these interim procedures
would also be applied to qualiﬁed health claims for conventional foods.285 In December of 2002, the FDA
also instituted “the Consumer Health Information for Better Nutrition Initiative, to make available more
and better information about conventional human food and human dietary supplements.”286 This initiative
resulted in the issuance in 2003 of the promised interim procedures for health claims in dietary supplements
and conventional foods.287 As of April 2004, these procedures are currently in eﬀect on an interim basis.
281Pearson v. Shalala, 164 F.3d 650 (D.C. Cir. 1999). The court went on to invalidate the FDA’s decision not to authorize,
under the NLEA, health claims for dietary ﬁber and cancer, antioxidant vitamins and cancer, omega-3 fatty acids and coronary
heart disease, and folate neural tube defects. Id. The FDA subsequently revoked its decision not to authorize such health
claims. 65 Fed. Reg. 58,917 (Oct. 3, 2000). In 2000 and 2001, the FDA announced its decision on these health claims in
several letters and Talk Papers. See http://www.cfsan.fda.gov/∼dms/ds-labl.html#qualiﬁed for a speciﬁc list of letters and
Talk Papers (last visited April 26, 2004).
28268 Fed. Reg. 66,040, 66,041 (Nov. 25, 2003).
28365 Fed. Reg. 59,855 (Oct. 6, 2000).
28467 Fed. Reg. 78,002 (Dec. 20, 2002).
285Id. at 78,003.
28668 Fed. Reg. 41,387 (July 11, 2003).
287Id. Center for Food Safety and Applied Nutrition, Food and Drug Administration, Interim Procedures for
43The interim procedures provide that the FDA will regulate qualiﬁed health claims for dietary supplements
and conventional foods “based on the extent to which the totality of the publicly available evidence supports
the claim [and]... [d]iﬀerent levels of evidence will result in diﬀerent qualifying language.”288 The interim
procedures outline the general process for petitioning the FDA for a qualiﬁed health claim,289 and they create
an evidence-based ranking system to “rate the strength of the evidence behind a proposed substance/disease
relationship.”290 The result of the evidence-based ranking system is placement of the qualiﬁed health claim in
one of three categories: (1) a moderate or good level of comfort that the claimed relationship is scientiﬁcally
valid,291 (2) a low level of comfort that the claimed relationship is scientiﬁcally valid,292 or (3) an extremely
low level of comfort that the claimed relationship is scientiﬁcally valid.293
Qualified Health Claims in the Labeling of Conventional Human Food and Human Dietary Supplements Guidance
(July, 2003), available at http://www.cfsan.fda.gov/∼dms/hclmgui3.html [hereinafter Interim Procedures]; Center for
Food Safety and Applied Nutrition, Food and Drug Administration, Interim Evidence-based Ranking System for
Scientific Data Guidance (July 2003), available at http://www.cfsan.fda.gov/∼dms/hclmgui4.html [hereinafter Interim
Evidence]. Both of these guidance documents apply to qualiﬁed health claims for dietary supplements or conventional foods.
288Interim Procedures, supra note 287.
289Id. The general petition procedure is as follows: (1) ﬁling of the petition for review with a response from the FDA on
completeness of the petition within 45 days; (2) prioritization by the FDA concerning review of the petition; (3) a sixty day
public comment period; (4) scientiﬁc review by the FDA after the close of the comment period; (5) notiﬁcation of a regulatory
decision by the FDA within 270 days of receipt of the petition; (6) availability of reconsideration of the FDA’s decision.
Id. Additionally, the substance of the petition is to comply with regulations for health claims under the signiﬁcant scientiﬁc
agreement standard of the NLEA; however, the petition need only demonstrate credible evidence supporting the claim. Id. For
the NLEA regulations for health claims, see 21 C. F. R. § 101.70.
290Interim Evidence, supra note 287. A simpliﬁed version of the evidence-based system is as follows: (1) deﬁne the relation-
ship between the dietary supplement or conventional food at issue and the disease at issue; (2) collect and submit all relevant
studies concerning the substance/disease relationship to be tested; (3) rate each study based on its experimental design; (4) rate
each study for overall quality; (5) rate the strength of the total body of evidence based on quantity, consistency, and relevance
to disease reduction; (6) rank the strength of the evidence for a health claim; (7) report the rank. Id.
291Id. An example of a label statement in this category is “although there is scientiﬁc evidence supporting the claim, the
evidence is not conclusive.” Interim Procedures, supra note 287.
292Interim Evidence, supra note 287. An example of a label statement in this category is “[s]ome scientiﬁc evidence suggests...
however, FDA has determined that this evidence is limited and not conclusive.” Interim Procedures, supra note 287.
293Interim Evidence, supra note 287. An example of a label statement in this category is “[v]ery limited and preliminary
scientiﬁc research suggests... FDA concludes that there is little scientiﬁc evidence supporting this claim.” Interim Procedures,
supra note 287.
44Under the current interim procedures, the FDA issues letters in response to petitions for qualiﬁed health
claims.294 As of April 2004, the FDA has received numerous petitions and has approved seven qualiﬁed
health claims for dietary supplements.295
The FDA has issued an advance notice of proposed rulemaking (“ANPRM”) soliciting comments on per-
manent, long-term procedures for qualiﬁed health claims for dietary supplements and conventional foods.296
The ANPRM listed three options under consideration: (1) incorporate, through notice and comment rule-
making, the current interim standards and procedures, including the evidence-based ranking system, (2)
change, through notice and comment rulemaking, the current signiﬁcant scientiﬁc agreement standard for
health claims under the NLEA to look at “the accuracy of the characterization of the evidence supporting the
claim, instead of the underlying substance-disease relationship,” or (3) examine qualiﬁed health claims on a
post-market basis wholly outside the NLEA health claims provisions.297 After an extension, the comment
period for this ANPRM ended February 25, 2004.298 As of April 2004, a proposed rule had not yet issued.
6. Good Manufacturing Practices
The DSHEA did not enact good manufacturing practices (“GMPs”) for dietary supplement but rather sub-
jected dietary supplements to GMPs for conventional food with the proviso that the Secretary could issue
294Interim Procedures, supra note 287.
295Center for Food Safety and Applied Nutrition, Food and Drug Administration, Summary of Qualified Health
Claims Permitted (Sep. 2003), available at http://www.cfsan.fda.gov/∼dms/qhc-sum.html; Qualiﬁed Health Claims, Food
Technology, Dec. 2003, at 90. Additionally, as of April 2004, eight petitions for qualiﬁed health claims are open for comment.
29668 Fed. Reg. 66,040 (Nov. 25, 2003).
297Id. at 66,042.
29869 Fed. Reg. 3868 (Jan. 27, 2004).
45GMPs regulations speciﬁcally for dietary supplements.299 The FDA issued an ANPRM in 1997 inviting
comments regarding the need for rulemaking for minimum GMPs for dietary supplements and dietary ingre-
dients.300 Prior to the ANPRM, the FDA had received a draft proposal on dietary supplement GMPs from
the dietary supplement industry.301 In 2003, after a six year delay, the FDA ﬁnally issued proposed rules
for dietary supplement GMPs.302 The purpose of the proposed rules are “to the ensure that manufacturing
practices will not result in an adulterated dietary supplement and that supplements are properly labeled.”303
The proposed rules focus on the personnel, equipment, production and process controls, holding and dis-
tributing, consumer GMPs complaints, and recordkeeping.304 After an extension, the comment period for
the proposed rules ended August 11, 2003.305 As of April 2204, the FDA has yet to take any further action.
7. Speciﬁc Dietary Supplements
Since the DSHEA, the FDA has issued several regulations concerning speciﬁc groups of dietary supple-
ments. In 1997, the FDA issued a ﬁnal rule requiring label warnings on certain iron containing dietary
supplements.306 The FDA issued this ﬁnal rule to prevent accidental overdose of iron-containing dietary
299Pub. L. No. 103-417, § 9 (codiﬁed at 342(g)). GMPs for conventional foods are codiﬁed at 21 C. F. R. § 110.
30062 Fed. Reg. 5700 (Feb. 6, 1997).
301Id. at 5700. In 1999, the CDSL had addressed dietary supplement GMPs in its ﬁnal report. CDSL Report, supra note 73.
The CDSL supported the eﬀort of the FDA and industry to develop GMPs for dietary supplements. Id. at 21. The CDSL also
stated the substantiation ﬁles for statements of nutritional support regarding dietary supplement should contain “[a]ssurance
that GMPs were followed in the manufacture of product.” Id. at 44.
30268 Fed. Reg. 12,157 (March 13, 2003).
303Id. at 12,164 (March 13, 2003). The rules state that a “manufacturer of... a dietary supplement cannot make claims that
state or imply that the... dietary supplement is safe and/or eﬀective simply because it has been manufactured in compliance with
current good manufacturing practice.” Id. However, a compliance statement might be lawful in context and with disclaimers.
Id.
304Id. at 12,164-12,165, 12,175-12,218.
30568 Fed. Reg. 27,008 (May 19, 2003).
30662 Fed. Reg. 2217 (Jan. 15, 1997). Parts of this ﬁnal rule were revoked in 2003 to comply with a U.S. Court of Appeals
ruling. 68 Fed. Reg. 59,714 (Oct. 17, 2003); see Center for Food Science and Applied Nutrition, Food and Drug
Administration, Iron-Containing Supplements and Drugs: Label Warning Statements – Small Entity Compliance
Guide (Oct. 17, 2003), available at http://www.cfsan.fda.gov/∼dms/secgiro2.html.
46supplements leading to poising and death in children under six years of age.307
The FDA recently issued a ﬁnal rule deeming dietary supplements containing Ephedrine Alkaloids (popularly
know as Ephedra) to be adulterated “because they present an unreasonable risk of illness or injury under
the conditions of use recommended or suggested in labeling, or... under ordinary conditions of use.”308 This
ﬁnal rule utilized the DSHEA provisions for dietary supplement safety.309 The FDA had moved as early as
1997 to ban Ephedrine Alkaloids under dietary supplement safety provisions by issuing proposed rules,310
but the FDA faced several diﬃculties, not the least of which was that under the DSHEA, the FDA had the
burden of proof in banning Ephedrine Alkaloids.311
Finally, the FDA has recently taken action regarding weight loss dietary supplements. On April 1, 2004,
the FDA announced that it had recently sent warning letters to sixteen weight loss dietary supplement
manufacturers.312 Such warning letters stated that insuﬃcient substantiation under the FDA notiﬁcation
and substantiation regulations for dietary supplement structure/function claims.313
30762 Fed. Reg. 2217 (Jan. 15, 1997).
30869 Fed. Reg. 6787, 6788 (Feb. 11, 2004).
309Pub. L. No. 103-417, § 4 (codiﬁed at 21 U. S. C. § 342(f)). The ﬁnal rule speciﬁcally utilizes the “unreasonable risk”
standard for dietary supplements in 21 U. S. C. § 342(f)(1)(A). The ﬁnal rule does not utilize the “signiﬁcant risk” standard
under 21 U. S. C. § 342(f)(1)(A), the “imminent hazard to public health or safety” standard under 21 U. S. C. § 342(f)(1)(C),
or the adulteration standard for conventional foods under 21 U. S. C. § 342(a)(1) as applied to dietary supplements under 21
U. S. C. § 342(f)(1)(D). Further, because Ephedrine Alkaloids were not considered new dietary ingredients, the new dietary
ingredient safety provisions under 21 U. S. C. § 342(f)(1)(B) and 21 U. S. C. § 350b were not applicable.
31062 Fed. Reg. 30,677 (June 4, 1997).
311The FDA withdrew part of its proposed rule in 2000 due to receipt of new adverse event reports regarding Ephedrine
Alkaloids and then twice reopened the comment period before issuing the ﬁnal rule in 2004. 65 Fed. Reg. 17,474 (April 3,
2000); 65 Fed. Reg. 46,721 (July 31, 2000); 68 Fed. Reg. 10,417 (March 5, 2003).
312Press Release, Food and Drug Administration, FDA Warns Distributors of Dietary Supplements Promoted Online for
Weight Loss (April 1, 2004), available at http://www.fda.gov/bbs/topics/news/2004/NEW01045.html [hereinafter Weight Loss
Press Release].
313See id. For the notiﬁcation and substantiation regulations, see discussion supra, Parts III.B.4, III.C.4. These warn-
ing are especially important because there is mounting evidence that weight loss dietary supplements are not actually
safe and eﬀective. See Salynn Boyles, Do Weight Loss Supplements Work?, WebMDHealth (April 2, 2004), available at
http://my.webmd.com/content/article/85/98401.htm (last visited April 26, 2004). For more on the FDA’s regulation of weight
loss dietary supplements and the improvements needed, see When Diets Turn Deadly: Consumer Safety and Weight Loss Sup-
478. Dietary Supplement Safety
While the DSHEA did enact new safety standards for dietary supplements,314 the FDA has not passed
general regulations concerning such safety standards.315 Generally, the FDA must gather data on its own
or through voluntary adverse event reporting from industry and then issue warning letters to manufactures.
The FDA has issued many such letters as well as taken other actions since passage of the DSHEA.316 When
the FDA feels it has gathered enough evidence to deem a dietary supplement unsafe, it can remove the
substance from the market as it did with Ephedrine Alkaloids. The FDA’s handling of Ephedrine Alkaloids
seems to indicate that it is content to rely on the statutory language of the DESHA for guidance and passive
post-marketing surveillance systems.317 However, in 1997 the FDA did issue one regulation concerning
dietary supplement safety.318 This regulation preserved the deﬁnition of “imminent hazard,” which is one
method by which a dietary supplement can be deemed adulterated under the DSHEA.319 More recently, the
FDA reaﬃrmed its commitment to dietary supplement safety.320
plements, Hearing Before Senate Subcomm. on Oversight of Gov’t Mgmt., Restructuring and the Dist. of Columbia, Comm.
on Gov’t Aﬀairs, 107th Cong. (2002) [Hereinafter House Weight Loss Hearing].
314Pub. L. No. 103-417, § 4 (codiﬁed at 21 U. S. C. § 342(f)).
315Instead the FDA has passed speciﬁc regulations that impact on dietary supplement safety (such as with GMPs, Ephedra,
and new dietary ingredients).
316See Office of the Inspector General, Department of Health and Human Services, Adverse Event Report for
Dietary Supplements – An Inadequate Safety Valve Appendix B (April 2001) [hereinafter OIG Adverse Event Report].
Recently, the FDA has taken such action with certain weight loss dietary supplements and androstendione. Weight Loss Press
Release, supra note 312; Press Release, Department of Health and Humans Services, HHS Launches Crackdown on Products
Containing Andro (March 11, 2004), available at http://www.fda.gov/bbs/topics/news/2004/hhs 031104.html.
317See discussion supra, Part. III.C.7, particularity note 309. As to passive post-marketing surveillance systems, see discussion
infra Part III.E.1. In 1999, the CDSL endorsed such an approach to dietary supplement safety. CDSL Report, supra note 73,
at vi.
31862 Fed. Reg. 39,439 (July 23, 1997).
319Id.; see 21 C. F. R. § 2.5. The DSHEA references this term in section 4 (codiﬁed at 21 U. S. C. § 342(f)(1)(C). Dietary
supplement safety may also be subject to the Public Health Security and Bioterrorism Preparedness and Response Act of 2002,
Pub. L. No. 107-188, 116 Stat. 594 (June 12, 2002). The FDA issued interim ﬁnal rules under this Act in 2003. See 68 Fed.
Reg. 58,893 (Oct. 10, 2003).
320Press Release, Food and Drug Administration, Acting FDA Commissioner Dr. Lester M. Craw-
ford Outlines Science-Based Plan for Dietary Supplement Enforcement (April 19, 2004), available at
http://www.fda.gov/bbs/topics/news/2004/NEW01055.html.
48D. Congressional Activity Regarding Dietary Supplements Post-DSHEA
While Part III.C above detailed the FDA’s response to the DSHEA, this section provides a cursory view of
congressional activity regarding dietary supplements post-DSHEA. Aside from the FDAMA, which is dealt
with separately above, little legislation aﬀecting dietary supplements has been enacted since the DSHEA.321
One applicable piece of legislation is the Farm Security and Rural Investment Act of 2002.322 This act
deemed a dietary supplement to be misbranded [i]f it purports to be or is represented as ginseng, unless
it is an herb or herbal ingredient derived from a plant classiﬁed within the genus Panax.323 The FDA
subsequently proposed to incorporate this statutory restriction into regulations.324
1. Past and Pending Proposed Bills Concerning Dietary Supplements
In 1995, shortly after the DSHEA, a bill entitled The Food and Dietary Supplement Consumer Information
Act of 1995 was introduced in the U.S. House of Representatives.325 The bill would have removed dietary
supplements from the deﬁnition of food while also prohibiting them from being deemed drugs, thus creating
a truly independent category of substances.326 The bill would also have repealed provisions of the DSHEA
concerning nutrition content claims and health claims instead holding such claims to a new uniform stan-
321The FDAMA and how it aﬀected dietary supplements is discussed supra, Parts III.C.3, III.C.5.ii. Also the Public Health
Security and Bioterrorism Preparedness and Response Act of 2002 and its eﬀects on dietary supplements is discussed supra
Part III.C.8, at note 319.
322Pub. L. No. 170-171, § 10806, 116 Stat. 143 (2002).
323Id. at § 10806(b)(2). The Act also stated that “the term ‘ginseng’ may only be considered to be a common or usual name
(or part thereof) for any herb or herbal ingredient derived from a plant classiﬁed within the genus Panax; and... only labeling
or advertising for herbs or herbal ingredients classiﬁed within that genus may include the term ‘ginseng’.” Id. at § 10086(b)(1).
32468 Fed. Reg. 51,738 (Aug. 28, 2003).
325H.R. 1951, 104th Cong. (1995).
326Id.
49dard.327 No action was taken on this bill.
In subsequent years from 1995 through the present, numerous bills have been introduced in Congress per-
taining to dietary supplements, but none have become law.328 There are also a number of bills concerning
dietary supplements pending in the current Congress.329
2. Congressional Hearings Concerning Dietary Supplements
Since the DSHEA, there have also been a number of congressional hearings examining a variety of aspects
of dietary supplements. The number of hearings are too numerous to list here,330 but a most recent hearing
327Id. CDSL Report, supra note 73, at 13. The proposed standard was that label claims must be truthful and not misleading.
H.R. 1951, 104th Cong. (1995).
328See, e.g., the Nutraceutical Research and Education Act, H.R. 3001, 106th Cong. (1999) (to establish a new legal classiﬁ-
cation and regulatory scheme for dietary supplements and foods with health beneﬁts); the Consumer Health Free Speech Act,
H.R. 1077, 106th Cong. (1999) (speciﬁcally excluding dietary supplements from the deﬁnition of drugs for purposes of making
structure function claims and also increasing the burden of proof on the FDA to demonstrate a dietary supplement is adul-
terated); the Dietary Supplement Fairness in Labeling and Advertising Act, H.R. 3305 (1999), 106th Cong. (1999) (loosening
both the restrictions on the regulation of scientiﬁc studies as labeling when used in conjunction with dietary supplements and
the restrictions on dietary supplement advertising); the Consumer Freedom Protection Act, H.R. 4604, 106th Cong. (2000) (to
allow for qualiﬁed health claims for dietary supplements consistent with Pearson v. Shalala); the Dietary Supplement Informa-
tion Act, H.R. 3065, 107th Cong. (2001) (to require dietary supplement manufacturers to register with the FDA and supply
the FDA with adverse event reports); the Health Information Independence Act of 2001, H.R. 3811, 107th Cong. (2002) (to
establish a health claim review system for food and dietary supplement independent of the FDA).
329See, e.g., the Dietary Supplement Information Act, H.R. 724, 108th Cong. (2003) (reintroduction of H.R. 3065, supra note
328); the Dietary Supplement Access and Awareness Act, H.R. 3377, 108th Cong. (2003) (to require manufacturers of dietary
supplement to submit adverse event reports to the FDA and allowing for the Secretary to ban sales of dietary supplements to
minors); the Health Information Independence Act, H.R. 4004, 108th Cong. (2004) (reintroduction of H.R. 3811, supra note
328); the DSHEA Full Implementation and Enforcement Act of 2003, S. 1538, 108th Cong. (2003) (to authorize appropriations
and institute accountability to ensure that the goals of the DSHEA are met); the Dietary Supplement Tax Fairness Act of
2003, H.R. 2627, 108th Cong. (2003) (to treat amounts paid for dietary supplements as medical expenses for tax purposes).
Additionally, prior to the FDA’s issuance of its ﬁnal rule on Ephedrine Alkaloids, numerous bills on this subject were introduced
in the 108th Congress. See, e.g., the Ephedrine Alkaloids Consumer Protection Act, H.R. 275, 108th Cong. (2003).
330See, e.g., Dietary Supplement Health and Education Act: Is the FDA Trying to Change the Intent of Congress?, Hearing
Before the House Comm. on Gov’t Reform, 106th Cong. (1999); Six Years After of DSHEA: The Status of National and
International Dietary Supplement Research and Regulation, Hearing Before the House Comm. on Gov’t Reform, 107th Cong.
(2001); Hearing on Diet, Physical Activity and Dietary Supplements Before the House Comm. on Gov’t Reform, 107th Cong.
(2002); House Weight Loss Hearing, supra note 313; Hearing on Dietary Supplements Containing Ephedra Before Senate
Subcomm. on Oversight of Gov’t Mgmt., Restructuring and the Dist. of Columbia, Comm. on Gov’t Aﬀairs, 107th Cong.
(2002); Joint Hearing on Issues Relating to Ephedra Dietary Supplements Before House Subcomm. on Commerce, Trade, and
Consumer Prot., Comm. on Energy and Commerce, 108th Cong. (2003).
50in 2004 is instructive.331 This hearing was held on the 10th anniversary year of the DSHEA to ensure
“federal health agencies and the dietary supplement industry have maintained the integrity of this act, so
that Congress might consider ways in which the act could be improved and educate American consumers
to the latest developments in dietary supplement policy and nutritional labeling practices.”332 One U.S.
House Rep. noted that regarding dietary supplement safety, the DSHEA forces the FDA to act after the fact
when substantial harm may have already occurred.333 In that regard, another congressman noted that he
would like to see mandatory adverse event reporting for dietary supplement manufacturers.334 However, the
director of the FDA Center for Food Safety and Applied Nutrition (“CFSAN”) testiﬁed that the FDA is not
seeking additional legislation for dietary supplements because it believes the DSHEA provides an adequate
framework.335
E. Additional Post-DSHEA Industry Activity Regarding Dietary Supplements
This section presents a fraction of the notable industry activity that has taken place regarding dietary
supplements post-DSHEA.
1. Dietary Supplement Safety and Adverse Event Reporting
Post-DSHEA, there has been considerable industry involvement regarding the safety of dietary supplements.
First, after passage of the DSHEA, the FDA was faced with a sizable challenge regarding dietary supplement
331Hearing on Dietary Supplements Before the House Subcomm. on Human Rights and Wellness, Comm. on Gov’t Reform,
108th Cong. (2004) [hereinafter 2004 House Hearing].
332Id. at 3 (statement of Rep. Dan Burton, Chairman, House Comm. on Gov’t Reform).
333Id. at 6 (statement of Rep. Susan Davis).
334Id. at 10 (statement of Sen. Richard Durbin). One industry group supported this. Id. at 41 (statement of Annette
Dickinson, President, Council for Responsible Nutrition).
335Id. at 15-16 (statement of Dr. Robert Brackett, Director, FDA Center for Food Safety and Applied Nutrition). Dr.
Brackett did concede that the voluntary adverse reporting system was not particularity robust, but he did point out that a new
adverse event reporting system is now in place for dietary supplements. See id. at 18, 20.
51safety. Speciﬁcally, it was not enabled by the DSHEA to institute a premarket review system for dietary
supplements marked for use in the United States prior to October 15, 1994.336 To decide then how to ensure
the safety of such dietary supplements, the FDA turned to the National Academies, including the Institute
of Medicine (“IOM”), to develop a framework for evaluating dietary supplement safety. In 2002 the IOM
issued a proposed framework,337 and just recently the IOM released its ﬁnal report.338 The report contains
a detailed framework for the FDA to follow in order to ensure the safety of dietary supplements339
As mentioned in Part III.C.8, the FDA must rely on post-market surveillance and voluntary adverse event
reporting to review the safety of dietary supplements (at least for those dietary supplements not falling within
the new dietary ingredient provision of the DSHEA). Two major reports have addressed the eﬀectiveness of
such a system for dietary supplement safety. First, in 2000 the General Accounting Oﬃce (“GAO”) issued
a report on the safety of dietary supplements and functional foods.340 The report concludes that there is
limited assurance of safety for dietary supplement and functional foods.341 The report attributed this to
the absence of guidance and regulations for dietary supplements in many areas including removal of unsafe
336See Pub. L. No. 103-417, § 4 (codiﬁed at 21 U. S. C. § 342(f)), § 8 (codiﬁed at 21 U. S. C. § 350b).
337Institute of Medicine, Proposed Framework for Evaluating the Safety of Dietary Supplements (2002).
338Institute of Medicine, Dietary Supplements: A Framework for Evaluating the Safety of (2004) [hereinafter
IOM Report].
339Id. In short, the FDA can either proactively initiate a review of a dietary supplement or can wait to receive a signal
indicating the possibility of serious health problem regarding the dietary supplement. Id. at 3-3 to 3-4. The FDA would then
make an initial review of the available information and determine the level of concern it has about the dietary supplement. Id.
at 3-5. If the level of concern is low, the FDA could monitor and continue to collect data. Id. If the level of concern is high
the FDA could take immediate action. Id. If the level of concern is moderate or it is high but the FDA does not want to take
immediate action, the FDA would engage in an integrative evaluation. Id. at 3-5 to 3-6. The integrative evaluation contains
four parts: “in-depth literature search and review, drafting of a safety monograph based on this information, integrating the
available data into an analysis to complete the monograph, and possibly referring the draft monograph to an expert committee
for additional input.” Id. at 3-6. The FDA is to enter at step three, examine the draft monograph, and then take regulatory
action, take no action and continue to monitor, or proceed with step four by referring the monograph to an expert committee for
review. Id. at 3-9 to 3-10. If the FDA proceeds with step four, the expert committee is to submit a report to FDA after which
the FDA will decide whether to take action or to continue to monitor. Id. at 3-11. As part of its report, the IOM prepared six
prototype monographs for the dietary supplements chaparral, chromium picolinate , glucosamine, melatonin, saw palmetto, and
shark cartilage. Id. at appendices D to I. The full monographs are available at http://www.iom.edu/subpage.asp?id=19554
(last visited April 22, 2004).
340United States General Accounting Office, Food Safety – Improvements Needed in Overseeing the Safety of
Dietary Supplement and Functional Foods (July 2000) [hereinafter GAO Safety Report].
341Id. at 12.
52products and the making of structure/function claims as well as a lack of a clearly deﬁned boundary between
dietary supplements and functional foods in conventional form.342
A second major safety report was issued in 2001 by the Oﬃce of the Inspector General of the Department
of Health and Human Services. It concerned the FDA’s adverse event reporting system for dietary sup-
plements.343 “An adverse event is an incident of illness or injury that may be associated with a product
or ingredient.”344 The FDA must rely on consumers, health professionals, and dietary supplement manu-
facturers for these reports as such reporting is entirely voluntary.345 The 2001 report concludes that the
FDA’s adverse event reporting detected only a small amount of such events for dietary supplements and
as a result the FDA rarely took responsive safety actions.346 Such problems were attributed to the limited
information the FDA receives and the lack of a well developed system for analyzing such information.347
The FDA responded to this report in announcing the creation of the CFSAN Adverse Event Reporting Sys-
tem (“CAERS”)348. CAERS is eventually to form a centralized reporting system for all CFSAN regulated
products (including all dietary supplements) by replacing previous decentralized and uncoordinated FDA
adverse event reporting systems.349 As of 2004, the eﬀectiveness of CARES has yet to be proven.350
342Id. at 13-25. Speciﬁcally, the report found that the FDA lacked guidance regarding the use and safety of new dietary
ingredients and also lacked consistent standards on the removal of unsafe dietary supplements. Id. at 15. Further, the report
found a lack of FDA guidance on requiring safety information on dietary supplement labels, lack of an eﬀective FDA system for
adverse event reporting, and lack of consistent FDA guidance on the making of structure/function claims on dietary supplement
labels. Id. at 15-21. Finally, the report found that the diﬀerence between structure/function claims and health claims was not
understood by consumers leading to consumer confusion over what such claims meant. Id. at 23-25. The report also made
formal recommendations to the FDA for correcting these deﬁciencies. Id. at 27. For the FDA’s response to a draft of this
report, see id. at appendix II.
343OIG Adverse Event Report, supra note 316.
344Id. at i.
345Id. at i, 4.
346Id. at ii-iii, 9-18.
347Id. at 9-18.
348Center for Food Safety and Applied Nutrition, Announcing CAERS – the Adverse Event Reporting System
(Aug. 29, 2002), available at http://www.cfsan.fda.gov/∼dms/caersltr.html.
349Id.
350See 2004 House Hearing, supra note 331, at 20 (statement of statement of Dr. Robert Brackett, Director, FDA Center for
Food Safety and Applied Nutrition).
53Finally, there are also industry based safety measures in place. The National Nutrition Foods Association
(“NNFA”) conducts the TruLabel program which all of its members (manufacturing dietary supplements un-
der their own label) must join.351 This program ensures that the dietary supplement labels of all participants
comply with all FDA regulations.352
2. Dietary Supplement Analysis
A further area of industry action regarding dietary supplements concerns dietary supplement analysis per-
formed by the Association of Analytical Communities International (“AOAC”). The AOAC is under contract
with the FDA and the National Institutes of Health to develop “reliable analytical methods... to verify in-
gredient identity and measure the amounts of declared ingredients” in dietary supplements.353 Such action
will certainly aid the FDA in ensuring dietary supplement safety.
F. Dietary Supplement Advertising Regulation
As with any consumer product, advertising plays an important role for dietary supplements. Not only do
retail outlets engage in advertising for dietary supplements, but so too do dietary supplement manufac-
tures through the use of medical journals, television, radio, magazines, retail trade publications, and public
relations campaigns.354
351National Nutritional Foods Association, NNFA TruLabel Program, available at
http://www.nnfa.org/services/science/bg TruLabel.htm#over (last visited April 22, 2004) [hereinafter TruLabel]. For
empirical information about dietary supplement labeling and claims (at least as of 1999) see Dietary Supplement Sales
Information, supra note 44, at 5-5 to 5-11.
352TruLabel, supra note 351. The NNFA also conducts a GMPs program for dietary supplement manufacturer mem-
bers. See National Nutritional Foods Association, NNFA GMP Certification Program Overview, available at
http://www.nnfa.org/services/science/gmp.htm (last visited April 22, 2004).
353James Giese, Dietary Supplement Analysis, Food Technology, Aug. 2003, at 92; AOAC International, Call for Methods
for Saw Palmetto, SAMe, Vitamin E, CoEnzyme Q10, Panaxquinquefolius, Panaz ginseng, Eleuthero, Kava Kava, Yohimbe
and Cranberry, available at http://www.aoac.org/dietsupp/Call 11 05 2003.pdf (last visited April 23, 2004).
354Economic Characterization, supra note 4, at 5-13.
54The Federal Trade Commission (“FTC”) is responsible for regulating advertising claims for all foods, in-
cluding dietary supplements. Speciﬁcally, the FTC may prohibit the dissemination of false or misleading
dietary supplement advertising.355 The FTC requires that dietary supplement advertising be truthful and
not misleading and have adequate substantiation for all claims.356 The FTC tries to harmonize its enforce-
ment of advertising claims with the FDA’s enforcement of claims in food and dietary supplement labels.357
However, there are situations where these enforcement approaches do not meet up.358
Several bills were introduced in Congress in the late 1990s to remedy diﬀerent standards of enforcement
between the FDA and FTC. In 1998 the Dietary Supplement Fairness in Advertising Act was introduced in
the U.S. House of Representatives.359 The bill would have ensured that dietary supplement advertising that
met the provisions of the FDCA and DSHEA and made certain disclosures about studies used in making
advertisement claims would not constitute unfair competition or deceptive trade practices under the FTC
statutory provisions.360 In 1999, the Dietary Supplement Fairness in Labeling and Advertising Act was
introduced in Congress to exempt all dietary supplement publications considered labeling under the DSHEA
(speciﬁcally 21 U. S. C. § 342-2) from regulation as advertising by the FTC.361 Neither of these bills became
law and no bills on this topic are currently pending in Congress.
35515 U. S. C. §§ 52, 55. Section 52 states that the dissemination of any false advertisement constitutes “an unfair or deceptive
practice” under 15 U. S. C. § 45 (granting general authority to the FTC to regulate unfair or deceptive practices).
356Federal Trade Commission, FTC Policy Statement on Deception (Oct. 14, 1983), available at
http://www.ftc.gov/bcp/policystmt/ad-decept.htm; Federal Trade Commission, FTC Policy Statement Re-
garding Advertising Substantiation (1983), available at http://www.ftc.gov/bcp/guides/ad3subst.htm; Fed-
eral Trade Commission, Dietary Supplements: An Advertising Guide for Industry 3, available at
http://www.ftc.gov/bcp/conline/pubs/buspubs/dietsupp.htm [hereinafter Advertising Guide]. Speciﬁcally, the FTC
will look to all express and implied claims made by the advertising, the types of disclosure made in the advertising, and
whether the advertiser has a reasonable basis for all express and implied claims. Advertising Guide, supra, at 3-18.
357See 59 Fed. Reg. 28,388 (June 1, 1994) (the FTC’s Enforcement Policy Statement on Food Advertising); GAO Safety
Report, supra note 340, at 22; Advertising Guide, supra note 356, at 24-25 (the FTC will generally follow the FDA’s labeling
approach under the DSHEA for third party advertising).
358For example, in some situations the FTC may allow a qualiﬁed health claim to be made in dietary supplement adverting
while the FDA would not allow such a claim on the dietary supplement label. GAO Safety Report, supra note 340, at 22.
As another example, use of the label disclaimer required under the DSHEA for statements of nutritional support in dietary
supplements may not constitute adequate disclosure under FTC advertising regulations. Advertising Guide, supra note 356,
at 23.
359H.R. 4581, 105th Cong. (1998).
360Id.
361H.R. 3305, 106th Cong. (1999). The same bill was introduced in the Senate. See S. 1749, 106th Cong. (1999).
55IV. RECOMMENDATIONS REGARDING FUTURE REGULATION OF DIETARY SUP-
PLEMENTS
This section discusses some recommendations for both the FDA and Congress concerning dietary supplement
regulation.
It could not be expected that the massive changes the DSHEA enacted for dietary supplement could be
swiftly and seamlessly detailed and implemented by the FDA. Ten years later, the FDA has made a serious
eﬀort to implement most all of the provisions of the DSHEA with varying amount of success and failure.
However, the FDA still has plenty of work to do regarding dietary supplements.
One area that needs further improvement is general dietary supplement safety. By excluding most dietary
supplements from drug regulations and excluding all dietary supplements from regulation as food additives,
the DSHEA greatly freed up manufacturers of dietary supplements. Dietary supplements are not subject
to premarket approval like drugs, nor must they be shown to be GRAS or otherwise comply with the Food
Additives Amendment of 1958 like all conventional food. However, this places an enormous safety burden
on the FDA, a burden which all too often the FDA has failed to carry.362 The FDA’s action regarding
Ephedrine Alkaloids demonstrated the costs of having to meet such heavy burdens.363 There are several
ways to remedy this. First, the FDA’s creation of CARES, a uniﬁed adverse event reporting system, is a step
in the right direction. Second, adverse event reporting should be made mandatory. All dietary supplement
362Some of this slack is picked up by the NNFA’s TruLabel program. See discussion supra Part III.E.1. This program should
certainly continue and expand in scope to reach industry wide.
363See discussion supra Part III.C.7.
56manufacturers should be required to submit adverse event reports to the FDA as they become available to
such manufacturers. Third, all manufacturers of dietary supplements should be required to register with the
FDA.364 This would greatly strengthen the FDA’s ability to detect signals relating to dietary supplement
safety. Fourth, the FDA should also adopt the detailed framework for dietary supplement safety recently
submitted to the FDA by the IOM, which would create a detailed FDA post-market surveillance system for
dietary supplements.365 Finally, while the FDA has implemented notiﬁcation procedures for new dietary
ingredients, it has not implemented guidance on the amount and type of evidence needed in this notiﬁcation
to demonstrate the safety of new dietary ingredients.366 Such guidance is greatly needed in order to provide
the dietary supplement industry with standards by which to test and produce new dietary supplements.
And additional area that needs improvement is the making of claims of nutritional support on dietary
supplement labels. Claims of nutritional support, and particularly structure/function claims and health
claims (both qualiﬁed and unqualiﬁed) are currently subject to varied and numerous regulations. However,
there is still consumer confusion and inability to distinguish between such claims.367 One possible solution
might be to create an agency independent of the FDA to handle and review statements of nutritional
support for dietary supplements in a consistent manner while clearly deﬁning the diﬀerences in each type
of claim.368 Harmonizing FDA and FTC regulations in this area would also be helpful and would lessen
consumer confusion.369
364A bill currently pending in the House would require this as well as mandatory adverse event reporting. See Dietary
Supplement Information Act, H.R. 724, 108th Cong. (2003). The Public Health Security and Bioterrorism Preparedness and
Response Act of 2002 and its registration requirements for food manufacturers are steps in this direction. See discussion supra
notes 319, 321.
365See IOM Report, supra note 338.
366The FDA was alerted to this need in 2000. See GAO Safety Report, supra note 340, at 27.
367See GAO Safety Report, supra note 340, at 23-25.
368A bill currently pending in the House would require this type of independent review system for health claims in dietary
supplements and other nutritional foods. See Health Information Independence Act, H.R. 4004, 108th Cong. (2004). A less
drastic but still satisfying solution would be the FDA’s ANPRM proposal of subjecting all qualiﬁed health claims to a new
post-market review system. See 68 Fed. Reg. 66,040 (Nov. 25, 2003); see also discussion supra Part III.C.5.iii.
369See discussion supra Part III.F for several bills that proposed a version of this.
57Finally, the FDA should work to better distinguish dietary supplements from conventional foods. As nu-
trition has become more important to society, the line between dietary supplements and functional yet
conventional foods has blurred. And while the DSHEA does require a dietary supplement to be labeled as
such, its allowance for dietary supplements to be marketed in conventional food form in certain circumstances
only adds to the confusion. The FDA should seek to explain these boundaries both for manufacturers and
for consumers through new regulations and public relations campaigns.370 Because of the similarity between
functional foods and dietary supplements, perhaps a new category of regulation should be created combining
these two product types.371 This new category could take these more “drug like” products for which struc-
ture/function and various health claims are made and subject them to uniform claim procedures separate
from conventional foods.
V. CONCLUSION
Dietary supplements are interstitial – spaced between conventional foods and drugs. However, this status
has not aﬀected their popularity, which has been and continues to be unprecedented. While Congress
and the FDA wrestled for decades with how to treat dietary supplements, they took a strong stance with
the DSHEA and subsequent regulations. The DSHEA considered dietary supplements to be food but also
subjected dietary supplements to some standards applied neither to food nor drugs. This categorization has
ﬁt, but imperfectly. The history of dietary supplement regulation since the DSHEA is one of trying to force a
previously undeﬁned product group into unsuitable clothing and of trying to ensure availability of a popular
product group while also ensuring safety. Real progress has been made, but the unsettling question still
370The FDA was alerted to this need in 2000. See GAO Safety Report, supra note 340, at 27.
371In 1999, a bill proposing a version of this was introduced in the House. See Nutraceutical Research and Education Act,
H.R. 3001, 106th Cong. (1999).
58remains: where is the line between a food and a drug? The DSHEA has given the FDA the tools to search
for the line, but in this era of emphasis on nutrition and functional foods additional, or at least refurbished,
tools may be required.
59